Role of prostanoids and kinins in the pharmacotherapy of heart failure by Davie, Andrew Peter
THE ROLE OF PROSTANOIDS AND KININS IN
THE PHARMACOTHERAPY OF HEART FAILURE
Dr Andrew P. Davie, MB ChB, MRCP
Doctor of Medicine








1.1 Nitric oxide and vascular tone
1.2 Prostacyclin and vascular tone
1.3 Endothelium derived hyperpolarising factor
1.4 Thromboxane and vascular tone
1.5 Neurohormonal activation and endothelial dysfunction
1.6 Other metabolites of arachidonic acid
1.7 Heart failure and prostaglandins
1.8 Vascular effects of aspirin
1.9 Vascular effects of ACE inhibitors
1.10 Differences between ACE inhibitors and ATI antagonists
1.11 Interaction between aspirin and ACE inhibitors
1.12 Interaction between aspirin and ATI antagonists








2.6 Measurement of blood flow
2.7 Analysis
2.8 Blood flow results
2.9 Alternative methods of blood flow measurement
2.10 Measurement of venous capacitance
2.11 Pulse and blood pressure measurement











3.3.2 Pilot and dose-ranging studies
3.3.3 Effect of arachidonic acid infusion
3.3.4 Effect of heart failure on response to arachidonic acid
3.3.5 Effect of aspirin on response to arachidonic acid
3.4 Discussion
3.4.1 Safety of arachidonic acid
3.4.2 Vasodilation by arachidonic acid
3.4.3 Effect of heart failure on response to arachidonic acid
3.4.4 Effect of aspirin on response to arachidonic acid
3.4.5 Comparison with effects of aspirin on prostacyclin
3.4.6 Comparison with effects of aspirin on bradykinin
3.4.7. Comparison with effects of aspirin on ACE inhibitors
3.4.8 Effects of aspirin on arachidonic acid
3.4.9 Summary










4.3.2 Effect of furosemide/GTN on forearm blood flow
4.3.3 Effect of furosemide/GTN on forearm venous capacitance
4.4 Discussion
4.4.1 Prostaglandins and venodilation
4.4.2 Angiotensin 11 and venodilation
4.4.3 Direct effects of furosemide
4.4.4 Effect of furosemide on endothelium
4.4.5 Summary










5.3.2 Effect of bradykinin
5.3.3 Effect of substance P
5.3.4 Effect of intra-arterial aspirin
5.3.5 Effect of intra-arterial aspirin on bradykinin/substance P
5.3.6 Effect of oral aspirin on bradykinin/substance P
5.4 Discussion
5.4.1 Effect of bradykinin in heart failure
5.4.2 Effect of substance P in heart failure
5.4.3 Effect of intra-arterial aspirin
5.4.4 Interaction of bradykinin and aspirin
5.4.5 Interaction of substance P and aspirin
5.4.6 Summary











6.3.2 Pilot and dose-ranging studies
6.3.3 Effect of bradykinin
6.3.4 Effect of Hoe-140
6.3.5 Effect of bradykinin after Hoe-140
6.4 Discussion
6.4.1 Effect of bradykinin in heart failure
6.4.2 Bradykinin and ACE inhibitors and ATI antagonists
6.4.3 Effect of bradykinin antagonism
6.4.4 Interaction of bradykinin antagonism and ACE inhibition
6.4.5. Local versus systemic effects
6.4.6 Effectiveness of bradykinin antagonism
6.4.7 Interaction between aspirin and ACE inhibitors
6.4.8. Summary










7.3.2 Effect of bradykinin
7.3.3 Effect of angiotensin^ 1 -7)
7.3.4 Effect of angiotensin^ 1-7) on bradykinin
7.4 Discussion
7.4,1 Effect of bradykinin in heart failure
4
7.4.2 Effect of angiotensin-(l-7) in heart failure
7.4.3 Angiotensin-(l-7) and bradykinin in heart failure
7.4.4 Summary











8.4.1 Acute versus chronic effects
8.4.2 Diurnal variation
8.4.3 Drug effects









9.3.2 Effect on plasma nitrate/nitrite concentrations
9.4 Discussion
9.4.1 Animal versus human studies
9.4.2 Blood pressure and aspirin therapy
9.4.3 Superoxide pathway of endothelial dysfunction
9.4.4 Summary
10 Conclusions
10.1 Effect of arachidonic acid in heart failure
10.2 Interaction of aspirin and furosemide in heart failure
10.3 Effect of bradykinin and substance P in heart failure
10.4 Effect of bradykinin antagonism in heart failure
10.5 Effect of angiotensin-(l-7) in heart failure
10.6 Endogenous fibrinolysis in heart failure






The work contained in this thesis was made possible by the Medical Research
Council through its Clinical Research Initiative in Heart Failure in Glasgow and my
appointment as clinical lecturer in cardiology in the same. Firstly, I would like to
express my heartfelt thanks to my supervisor, Professor John McMurray, who has
never failed to inspire me more than anyone else I know, ever since I first met him. I
would like to express special thanks to my colleague, Dr Michael Love, who helped
set up the clinical vascular laboratory, instructed me in the technique of venous
occlusion plethysmography, and enabled me to pass on these skills to other
colleagues in turn. I would like to thank Wendy Fallon and her colleagues in the
Sterile Dispensary of the Pharmacy Production Unit and Muire O'Connell and her
colleagues in the Clinical Trials Unit (both Western Infirmary of Glasgow) for their
invaluable assistance with drug preparation and dispensing. Most of all I would like
to thank all my patients, not only because clinical research can be wearing for both
doctor and patient at times, but also because their patience, forbearance and good
humour made the whole project a pleasure. Finally, I would like to thank my wife,




I hereby declare that this thesis was composed by myself, the work contained
was my own, I hold the degree ofMB ChB from the University of Edinburgh, and I
have not submitted this thesis in candidature for any other degree, diploma or
professional qualification. The only exception to this is the work contained in
chapter 4, which was conducted by a medical student, Mr Pardeep Jhund, under my
direct guidance and supervision. Otherwise, all physiological measurements and
blood sampling were conducted by myself, apart from the blood assays themselves.
The blood assays in chapter 8 were kindly performed by Dr Ann Rumley and
Professor Gordon Lowe, and the blood assays in chapter 9 were kindly performed by
Dr Ian Young.




Davie AP, Dargie HJ, McMurray JJV. Role of bradykinin in the vasodilator effects
of losartan and enalapril in patients with heart failure. Circulation 1999; 100:268-
273.
Davie AP, McMurray JJV. Effect of angiotensin^ 1-7) and bradykinin in patients
with heart failure treated with an ACE inhibitor. Hypertension 1999;34:457-460.
Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic
acid-induced vasodilation in heart failure. Clin Pharmacol Ther 2000;67:530-537.
Jhund PS, Davie AP, McMurray JJV. Aspirin inhibits the acute venodilator response
to furosemide in patients with chronic heart failure. JAm Coll Cardiol (in press)
Abstracts
Davie AP, Love MP, McMurray JJV. Aspirin and the Effects of Arachidonic Acid in
Patients with Heart Failure. Heart Failure Update '98: P51.
Davie AP, Love MP, McMurray JJV. Aspirin and Arachidonic Acid in Patients
With Heart Failure. Circulation 1998;98:1319.
Davie AP, McMurray. Contribution of bradykinin to the vasodilator effects of
enalapril and losartan in patients with heart failure. J Am Coll Cardiol
1999;33:235A.
Davie AP, Love MP, Cleland JGF, Dargie HJ, McMurray JJV. Arachidonic acid and
the effects of aspirin in patients with heart failure. Heart 1999;81 :P8.
8
Davie AP, McMurray JJV. Bradykinin and the vasodilator effects of enalapril
compared with losartan in patients with heart failure. Eur Heart J 1999;20A:27.
Jhund PS, Davie AP, McMurray JJV. Aspirin inhibits the acute venodilator response
to furosemide in patients with chronic heart failure. Circulation 1999; 100:153 6-
1537.
Jhund PS, Davie AP, McMurray JJV. Aspirin inhibits the acute venodilator response
to frusemide in patients with chronic heart failure. Heart 2000;83:P5.
9
Abstract
It has become clear that aspirin may have detrimental effects in heart failure. It has
also become clear that angiotensin converting enzyme (ACE) inhibitors and, perhaps,
angiotensin II type I receptor (ATI) antagonists may have beneficial "non-
angiotensinergic" effects, not directly related to suppression of angiotensin II levels
or blockade of the angiotensin II receptor. Some of these effects may be related to
prostaglandins and/or kinins, such as bradykinin or substance P, and might therefore
interact with the effects of aspirin. The studies described in this thesis aim to
disentangle some of these interactions. The study in chapter 2 examined the effect of
intra-arterial arachidonic acid on forearm blood flow in healthy volunteers and in
patients with heart failure treated with an ACE inhibitor. We found that arachidonic
acid was vasodilating and that this vasodilation was inhibited by 14 days oral aspirin,
even a dose as small as 75mg daily. This does not prove that aspirin adversely
affects vascular tone in these patients, but it does prove that it could. The study in
chapter 3 examined the effect of aspirin on the immediate venodilator response to
intravenous furosemide in patients with heart failure treated with an ACE inhibitor.
We found that there was a small immediate venodilator response to intravenous
furosemide, and we found that this vasodilator response was inhibited by 14 days
oral aspirin, even a dose as small as 75mg daily. This proves that aspirin adversely
affects the haemodynamic response to furosemide in these patients. The study in
chapter 4 examined the effect of bradykinin and substance P on forearm blood flow
in patients with heart failure treated with an ACE inhibitor, and the effect of aspirin.
We found that bradykinin and substance P were potent vasodilators, but that neither
was affected by aspirin. This implies that neither bradykinin nor substance P is
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likely to contribute to a negative interaction between aspirin and ACE inhibitors.
The study in chapter 5 examined the effects of bradykinin and its antagonist on
forearm blood flow in patients with heart failure randomised to double-blind
crossover treatment with ACE inhibitor or ATI antagonist. Whilst we found that the
response to bradykinin was enhanced by ACE inhibitor, as expected, we found no
significant effect of bradykinin antagonism with an ACE inhibitor or an ATI
antagonist. These results point out a discrepancy between potentiation of exogenous
bradykinin by ACE inhibitors and lack of potentiation of endogenous bradykinin by
either ACE inhibitors or ATI antagonists This implies that bradykinin is unlikely to
contribute to the non-angiotensinergic effects of ACE inhibitors (and unlikely to
contribute to a negative interaction with aspirin). The study in chapter 6 examined
the effect of intra-arterial bradykinin and angiotensin^ 1-7) on forearm blood flow in
patients with heart failure treated with an ACE inhibitor. We found that angiotensin-
(1-7) had no significant effect on forearm blood flow, and no significant effect on the
response to bradykinin. This implies that angiotensin^ 1-7) is unlikely to contribute
to the non-angiotensinergic effects of ACE inhibitors (and unlikely to contribute to a
negative interaction with aspirin). The studies in chapter 7 and 8 examined the effect
of ACE inhibitor and ATI antagonist on endogenous fibrinolysis and nitrate/nitrite
levels in patients with heart failure. We found no significant difference between the
two treatments with regard to endogenous fibrinolysis or nitrate/nitrite levels after 5
weeks of enalapril lOmg bd or in the same 12 patients after 5 weeks of losartan 25mg
bd. This means that the effect of ACE inhibitors on endogenous fibrinolysis and
nitrate/nitrite levels is unlikely to reflect a non-angiotensinergic effect (and unlikely
to interact with the effects of aspirin). In conclusion, we have shown that aspirin can
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effect vascular tone in patients with heart failure, but that if it does interact with the
effects ofACE inhibitors, it is unlikely to do so by an effect on bradykinin, substance
P or angiotensin^ 1-7). In addition, we have shown that there is a real discrepancy
between potentiation of endogenous bradykinin and potentiation of exogenous
bradykinin. Furthermore, we have been unable to find any difference between ACE




1.1 Nitric oxide and vascular tone
Vascular biology has come a long way from the time when the blood vessel
was regarded as a passive conduit, to today, when the endothelium can be regarded as
the largest endocrine organ in the body. The first major step on this pathway was the
realisation of the fact that vasodilation to acetylcholine was endothelium-dependent,
that is, literally dependent on the physical and vital integrity of vascular endothelium
(Furchgott & Zawadzki, 1980). This rapidly led to the postulation of an endothelium-
derived relaxing factor, which came to be known as EDRF, as the main mediator of
such effects. It was some time before the final characterisation of EDRF as nitric
oxide. This came with the demonstration that nitric oxide was indistinguishable from
EDRF in terms of biological activity, stability, and susceptibility to both an inhibitor
and a potentiator (Palmer et al, 1987). It is now clear that vascular tone is the end
result of a complex interplay of simultaneously vasoconstricting and vasodilating
factors. Some of these exert their effects on vascular smooth muscle directly
(endothelium-independent) and some stimulate vascular endothelium to release other
substances, which then influence vascular smooth muscle (endothelium-dependent)
(Table 1.1). There are therefore a number of endothelium derived relaxing and
contracting factors (Table 1.2), which mediate the effects of endothelium dependent
vasodilators and vasoconstrictors. It is clear that a number of substances may have
both endothelium-dependent and/or endothelium-independent effects, and both
vasodilating and/or vasoconstricting effects in different conditions or under different
circumstances, but endothelium derived relaxing factors are always vasodilating and
endothelium derived contracting factors are always vasoconstricting (unless, like
endothelin-1, it is also acting as an endothelium-dependent vasodilator). Furthermore,
impairment of endothelium-dependent (mainly vasodilator) responses and relative
preservation of endothelium-independent responses has come to be recognised as the
syndrome of endothelial dysfunction. Endothelial dysfunction is now well known as
the hallmark ofmany pathophysiological states in cardiovascular disease, and indeed a
number of other conditions as well (Table 1.3).
1.2 Prostacyclin and vascular tone
Over the past couple of decades much of the interest in vascular biology has
focussed on what was first called EDRF and eventually characterised as nitric oxide.
Over the same period, however, it has become clear that nitric oxide is far from being
the only relaxing factor derived from the endothelium. Even when it transpired that
EDRF and nitric oxide were one and the same thing, there remained evidence that
prostanoids derived from arachidonic acid by cyclooxygenase, and an as yet
uncharacterised substance specified as endothelium-derived hyperpolarising factor
(EDFFF), were also part of the communication between endothelium and associated
smooth muscle. Indeed, it was a little before the sequence of events referred to
above, that a substance first described as prostaglandin X (Moncada et al, 1976), and
then as prostaglandin 12 or prostacyclin (Whittaker et a/, 1976), was shown to be a
potent antiplatelet agent and a potent vasodilator (the name epoprostenol has also
been proposed). When it was revealed that prostacyclin was released by endothelial
cells (Weksler el al, 1977), the focus was initially on its antiplatelet effects (Moncada
et al, 1977). Subsequently its vasodilator effects came to the fore (Dusting et al,
1977), especially in the pulmonary circulation (Kadowitz et al, 1978). It is now clear
that prostacyclin fulfils the criteria of an endothelium-derived relaxing factor every bit
as much as nitric oxide.
1.3 Endothelium derived hyperpolarising factor
Somewhat later on than the above, the hyperpolarisation which had long been
known to accompany vasodilation (Funaki & Bohr, 1967), was first of all perceived
to be equally endothelium-dependent (Feletou & Vanhoutte, 1988), and then to be
distinct from the effects of nitric oxide itself (Komori et al, 1988). Despite this early
progress, endothelium-derived hyperpolarising factor (EDHF) has continued to elude
definitive characterisation, and it is not even clear whether there is one EDHF or
many. Early suggestions that EDHF might be ammonium ions (Feletou et al, 1989)
or peroxide ions (Beny & von der Weid, 1991) have not been supported. Another
line of enquiry suggests that EDHF might be derived from arachidonic acid via a
cytochrome P450 dependent mechanism, and that its action is associated with
calcium-activated potassium channel opening (Hecker et al, 1994). Two classes of
substance have been postulated to fulfil these criteria, epoxyeicosatrienoic acids
(EETs) (Campbell et al, 1996) and the endogenous cannabinoid anandamide (Randall
et al, 1996). The data remains fragmentary and contradictory as far as these and
other substances are concerned, however, and neither has been confirmed as ED1TF
(Zygmunt et al, 1996, Plane et al, 1997). More recently, it has been suggested that
EDHF might be C-type natriuretic factor but this does not seem to be the case either
(Barton et al, 1998). The most recent line of enquiry suggests that EDHF may be a
particle even simpler than the simple molecule of nitric oxide, i.e., the potassium ion
(Edwards et al, 1998). Whether or not EDHF is finally pinned down to a single
substance, it seems likely that the number of recognised endothelium derived relaxing
factors will continue to proliferate in the years ahead, as it has to date.
1.4 Thromboxane and vascular tone
Blood vessels are obviously not just under the influence of agonists that cause
vasodilation, but also agonists that cause vasoconstriction. This is reflected in the fact
that there are not just endothelium derived relaxing factors but also endothelium
derived contracting factors. The principal EDCF has been characterised as
endothelin-1 (Yanagisawa et al, 1988) and this has been a focus of almost as much
interest as nitric oxide, having been discovered around the same time. However, just
as it has become clear that there is a family of endothelium derived relaxing factors, it
has also become clear that there is a family of endothelium derived contracting
factors. Again, metabolites of arachidonic acid are notable players in this aspect of
endothelial control. Indeed, just as arachidonic acid may be metabolised by
endothelial cells to produce the EDRF prostacyclin (Weksler et al, 1977), it may
alternatively be metabolised by endothelial cells to produce the EDCF thromboxane
(Ingerman-Wojenski et al, 1981). This makes the role of arachidonic acid and its
metabolites in vascular biology in general and in endothelial control of smooth muscle
in particular all the more interesting.
1.5 Neurohormonal activation and endothelial dysfunction
We are particularly interested in the syndrome of congestive heart failure due
to left ventricular systolic dysfunction. It has long been recognised that heart failure is
characterised by an abnormality of vascular tone with excessive vasoconstriction
(Zelis et al, 1974). At one level this is simply due to the activation of multiple
endocrine pathways that has come to be known as neurohormonal activation (Thomas
el al, 1978). Initially the vasoconstriction and fluid retention that this produces are
compensatory mechanisms designed to maintain blood pressure and renal perfusion.
In both the short and long term, however, fluid retention and vasoconstriction are an
inappropriate response to the development of heart failure. Despite some initial
controversy, it has come to be accepted that this process contributes to progression of
the disease and is a reasonable target for therapy aimed at interruption of this
progression (Swedberg, 1988; Cohn, 1988; Packer, 1992). At the same time,
endothelial dysfunction has also come to be a well-recognised facet of the syndrome
of heart failure (Kaiser el al, 1989). It is obvious from Table 1.3 that many of the
individual causes of endothelial dysfunction (hypertension, diabetes, hyperlipidaemia,
smoking, ageing and atherosclerosis) are part of the syndrome of heart failure (it is
even hypothesised that endotoxaemia may also be an unexpected facet of the
syndrome of heart failure, Niebauer el al, 1999). Indeed, many of these factors
contribute to the development of heart failure itself for the majority of patients with
heart failure due to ischaemic heart disease. It is thus difficult to separate the effects
of one cause of endothelial dysfunction from the effects of another, especially in
patients with heart failure. It is also immediately obvious that there must be a close
communication between endothelial dysfunction and neurohormonal activation, to the
extent that it must be difficult to disentangle the effects of one from the other, or to
know to what extent one causes the other.
1.6 Other metabolites of arachidonic acid
The question also arises, to what extent abnormalities of prostaglandin
metabolism might arise from, or contribute towards, endothelial dysfunction. As we
have already seen, prostanoids participate in endothelial control of smooth muscle
relaxation (in the form of the endothelium derived relaxing factor, prostacyclin) and
contraction (in the form of the endothelium derived contracting factor, thromboxane).
We have also seen (Table 1.1) that the common precursor of all prostanoids,
arachidonic acid, has been described as an endothelium-dependent vasodilator (De
Mey & Vanhoutte, 1982), an endothelium-dependent vasoconstrictor (De Mey &
Vanhoutte, 1982), an endothelium-independent vasodilator (Pinto et al, 1986), or an
endothelium-independent vasoconstrictor (Boulanger & Vanhoutte, 1993). This
unique versatility (see Table 1.1 for comparisons) is a consequence of the fact that
arachidonic acid is not itself an agonist at any known receptor, but a common
precursor of the substances which are. Arachidonic acid is released by the action of
phospholipase on phospholipid from the cell membrane and metabolised to a number
of different sorts of receptor agonist, many of them vasoactive in their own right
(Figure 1.1). Apart from prostacyclin and thromboxane, there is prostaglandin H2
(Toda et a!, 1988), prostaglandin F2a (Ducharme et al, 1968), leukotriene C4 and D4
(Sakuma et al, 1987), 15-hydroxyeicosatetraenoic acid (15-FTETE) and 15-
hydroperoxyeicosatetraenoic acid (15-HPETE) (Van Diest et al, 1986), and 20-
hydroxyeicosatetraenoic acid (20-HETE) (Escalente et al, 1989). This is all quite
apart from the potential role of EETs and/or anandamide as alluded to earlier.
1.7 Heart failure and prostaglandins
It follows from the above that there are many different ways in which
abnormalities of prostaglandin metabolism might contribute to the endothelial
dysfunction (or indeed the smooth muscle cell dysfunction ?) of heart failure. This
rather begs the question, however, of whether or not there is any evidence that they
do so. There is evidence that interfering with prostaglandins in heart failure is
detrimental (Walshe & Venuto, 1979), and that exogenous prostaglandin
administration may be therapeutic in heart failure (Awan et al, 1981). Despite this,
the most well known attempt to demonstrate a mortality benefit (with long term
intravenous administration of synthetic prostacyclin) actually demonstrated excess
mortality (Califf et al, 1997). There appears to be rather less evidence that disorders
of prostaglandin production and function are an inherent part of the syndrome of heart
failure. Dzau et al (1984) found that heart failure was associated with increased
plasma levels of prostaglandin E2-metabolite and 6-keto-prostaglandin Fia (a
chemically stable metabolite of prostacyclin), and that the association was especially
strong in patients with hyponatraemia and activation of the renin-angiotensin-system
(in whom administration of the cyclooxygenase inhibitor indomethacin was associated
with haemodynamic deterioration). The findings of this study were corroborated by a
later study (Punzengruber et al, 1986) which found very similar associations with
plasma levels of bicyclo-prostaglandin E2 metabolite (a more stable prostaglandin E2
degradation product). One animal study (Holmer et al, 1987) found that plasma
levels of 6-keto-prostaglandin Fia increased in 4 out of 6 dogs during the first 4 days
of pacing-induced heart failure. An exercise study (Ueyuma et al, 1993) found not
only that plasma levels of 6-keto-prostaglandin Fia were elevated, but that their
exercise-induced elevation was further increased in patients with heart failure. The
most recent study (Castellani et al, 1997) found a correlation between functional class
of heart failure and urinary daily excretion of thromboxane and prostaglandin F2a.
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There therefore does seem to be evidence of an association between heart failure,
especially more severe heart failure (made manifest by hyponatraemia, renin-
angiotensin-system activation and/or worse functional class), and elevation of levels of
both vasodilator and vasoconstrictor prostaglandins. Since both vasodilator and
vasoconstrictor prostaglandins, as we have seen, may be released by endothelium, the
question certainly does arise to what extent the increased release of such substances
might represent an unimpaired or even an enhanced endothelial response. Such a
mechanism could be a compensation for other impaired aspects of endothelial
function, or an effector mechanism of neurohormonal activation (or both
simultaneously). This aspect of vascular function in heart failure is clearly deserving
of further study.
1.8 Vascular effects of aspirin
In connection with the above, we are particularly interested in the vascular
effects of aspirin in patients with heart failure. Aspirin (acetylsalicylic acid) is an
inhibitor of prostaglandin synthase (cyclooxygenase) (Vane, 1971) which is widely
used in cardiovascular pharmacology for its antiplatelet effects. This means that,
deliberately or not, it is used in many patients with heart failure as a consequence of
ischaemic heart disease. Until recently, it has always been assumed that aspirin has no
direct vascular effects, in heart failure, or in any other condition. However, it follows
from the preceding considerations that aspirin may have very important vascular
effects in heart failure. Only very recently has the idea that the effects of aspirin in
heart failure may not be entirely beneficial received an airing (Cleland el al, 1995). As
it turns out, however, aspirin does not appear to have any direct immediate vascular
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effects on its own. The reason for this is not clear, but it has necessitated the
examination of more complex interactions to pin down the role of aspirin therapy in
heart failure.
1.9 Vascular effects of ACE inhibitors
We are also particularly interested in the vascular effects of inhibitors of
angiotensin converting enzyme (ACE). Over recent years, ACE inhibitors have
consolidated their position as a cornerstone of the evidence-based treatment of heart
failure (Garg & Yusuf, 1995). More recently, the idea that ACE inhibitors might owe
some of their beneficial effects to restoration of impaired endothelial function has
gained some currency (Nakamura et al, 1991, Mancini et al, 1996). Despite this, it is
not at all clear whether such an effect would be due to suppression of angiotensin II
levels or to potentiation of bradykinin levels or both (ACE is responsible for the
breakdown of bradykinin as well as the production of angiotensin II). It is certainly
possible that not all of the beneficial effects of ACE inhibitors are necessarily due to
suppression of angiotensin II levels. Indeed, ACE inhibitors may not even necessarily
be very good at suppressing angiotensin II levels, because of non-ACE pathways of
angiotensin II generation (Van den Meiracker et al, 1992; Padmanabhan et al, 1999).
Some of the beneficial effects of ACE inhibitors may therefore be "non-
angiotensinergic", or at least "non-angiotensin-Il-ergic".
1.10 Differences between ACE inhibitors and ATI antagonists
More recently, angiotensin II type I receptor (ATI) antagonists have become
available. Whilst initially perceived as being very similar to ACE inhibitors, with time
it has become clearer that they may be very different. The reason for this is the
extraordinary complexity of the renin-angiotensin-system. It has become clear that
angiotensin I and II are not the only angiotensins. In fact, as shown in Table 1.4, at
least sixteen different angiotensins may result from the action of ACE, or other
endopeptidases, or carboxypeptidase, or aminopeptidase, on angiotensin 1. Most of
these have been detected in human plasma (Semple et al, 1976; Lawrence et a!, 1990),
and many of them have been demonstrated to be vasoactive, albeit in animals. It is
also clear that the level of many of these substances may be markedly increased by
ACE inhibitors (Lawrence et al, 1990). The effect of ATI antagonists on the levels
of such substances is completely unknown. It has also become clear that the ATI
receptor and the AT2 receptor are not the only angiotensin receptors. In fact, as
shown in Table 1.5, there are probably at least five different subtypes of angiotensin
receptor, and some of the less well known ones probably account for the action of
some of the less well known angiotensins. Given this complexity, it is not surprising
that it is not clear whether ATI antagonists are better than (e.g., Pitt et al, 1997), just
the same as (e.g., Pitt et al, 1999), or not as good as (e.g., McKelvie et al, 1999)
ACE inhibitors.
1.11 Interaction between aspirin and ACE inhibitors
If there are significant differences between ACE inhibitors and ATI
antagonists, they are likely to result from effects on bradykinin, or non-angiotensin II
angiotensins, or non-ATI angiotensin receptors. The effects of bradykinin are
frequently said to be prostaglandin dependent - it is not known whether any of these
other effects are or not. It follows from this that any differences between ACE
inhibitors and ATI antagonists stand a good chance of being prostaglandin-
dependent. At present it is not clear whether ACE inhibitors and ATI antagonists do
have effects distinct from one another or not, but if they do have, they might then be
expected to interact differently with the effects of aspirin. There have been a number
of small-scale haemodynamic studies to suggest an interaction between aspirin and
ACE inhibitors. Starting with Hall et al in 1992, the results of these have been
somewhat contradictory and are discussed in chapter 3 (section 3.4.7). There have
also been a number of post-hoc analyses of the interaction of aspirin and ACE
inhibitors in large-scale randomised controlled trials (of ACE inhibitors or other
agents). Results from SOLVD have been interpreted by some as showing an
interaction (Cleland et al, 1995; 1996), but by others as showing no interaction (Pitt,
1993; Al-Khadra et al, 1998). Results from CONSENSUS-2 have been interpreted as
showing an interaction (Nguyen et al, 1997), but CONSENSUS-2 was negative
overall, and therefore very much at odds with other studies of ACE inhibitors.
Results from CATS have been interpreted by some as showing an interaction
(Oorsterga et al, 1998), but by others as showing no interaction (Davie, 1999).
Results from BIP have been interpreted as showing no interaction (Leor et al, 1999),
but enthusiasm for these results must be tempered by the fact that BIP was a trial of
lipid-lowering therapy in patients with coronary disease but without heart failure.
Unfortunately it remains highly unlikely that there will ever be a large-scale
randomised controlled trial (2x2 factorial design) of the interaction of aspirin and
ACE inhibitors or angiotensin antagonists in patients with heart failure.
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1.12 Interaction between aspirin and ATI antagonists
There is currently no evidence at all on whether or not there is an interaction
between aspirin and ATI antagonists. Work in this field might be furthered, by direct
examination of interactions between aspirin and ACE inhibitors or between aspirin
and ATI antagonists, or by closer examination of the potential differences between
ACE inhibitors and ATI antagonists.
1.13 Aims and objectives
It is with the above considerations in mind that we have been interested in
examining the vascular effects of aspirin and ACE inhibitors and AT 1 antagonists, and
the interactions between them, in patients with heart failure. We have chosen to use
the technique of venous occlusion plethysmography for measurement of forearm
blood flow in patients with heart failure. This has the strength of examining clinical
pharmacology in humans rather than in animals, in vivo rather than in vitro, in real
patients rather than in some model of heart failure, and in a single predictable vascular
bed, rather than the more complicated and more unpredictable whole body. The
problem with this is that despite some isolated examples to the contrary (Bank et al,
1991, Duffy et al, 1998), the consensus of opinion is that aspirin does not have any
direct immediate effects on its own in this situation, and nor do ACE inhibitors
(Benjamin et al, 1989). The reasons for this are not immediately obvious, but might
be something to do with a dissociation between immediate and delayed effects.
Whatever the reasons, it clearly means that we need to examine rather more complex
interactions to shed light on the subject.
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1.14 Current studies
The current series of experiments was designed to attempt to delineate more
clearly the role of arachidonic acid and its metabolites in the vasculature of patients
with heart failure, and their modulation by aspirin therapy and/or ACE inhibitor
therapy and/or ATI antagonist therapy. In chapter 3, we examine the effects of
arachidonic acid itself in normals, in patients with heart failure, and the effect of
aspirin on the response to arachidonic acid in patients with heart failure (all treated
with ACE inhibitor). In chapter 4, we examine the effects of the same doses of aspirin
on the venodilator response to furosemide in patients with heart failure (seeking
clinical validation of the effect observed with arachidonic acid). In chapter 5, we
examine the effects of bradykinin and substance P (bradykinin is the principal
candidate for non-angiotensinergic effects of ACE inhibitors and may or may not have
prostaglandin-dependent effects itself - the same is possibly true of substance P) in
patients with heart failure, and the effects of aspirin on this response. In chapter 6, we
contrast the effects of bradykinin with the effects of bradykinin antagonism in patients
with heart failure, and the effects of ACE inhibition and ATI antagonism on this
response. In chapter 7, we examine the effects of angiotensin^ 1 -7) (angiotensin^ 1 -7)
is the principal candidate for non-angiotensin-II-ergic angiotensinergic effects of ACE
inhibitors and may or may not have prostaglandin-dependent effects itself) in patients
with heart failure. In chapter 8, we examine the effects of ACE inhibition and AT 1
antagonism on plasma fibrinolytic activity in patients with heart failure. Plasma
fibrinolytic activity is a further dimension of endothelial function, which is a
potentially important substrate for the effects of aspirin as well as ACE inhibitors
and/or ATI antagonists. In chapter 9, we examine the effects of ACE inhibition and
ATI antagonism on plasma nitrate concentrations, which appear to represent an
overall marker of the level of endothelial function, in patients with heart failure.
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Table 1.1 Endothelium dependent & independent vasodilators &
vasoconstrictors
Endothelium independent vasodilators
Atrial Natriuretic Factor (Winquist et al, 1984)
Arachidonic Acid (Pinto et al, 1986)
Vasoactive Intestinal Peptide (Sata et al, 1986)
(3 agonists (Carvalho et al, 1987)
Adenosine/AMP (Shirahase et al, 1988)
PACAP (Warren et al, 1991)
CGRP (Samuelson & Jernbeck, 1991)
Adrenomedullin (Hirata et al, 1995)
Endothelium dependent vasodilators
Acetylcholine (Furchgott & Zawadzki, 1980)
PDGF (Coughlin et al, 1980)
ADP/ATP (De Mey & Vanhoutte, 1981)
Thrombin (De Mey & Vanhoutte, 1981)
Bradykinin (Cherry et al, 1982)
Arachidonic Acid (DeMey & Vanhoutte, 1982)
Substance P (Angus et al, 1983)
Serotonin (Cocks & Angus, 1983)
a-agonists (Cocks & Angus, 1983)
Histamine (Van de Voorde & Lausen, 1983)
Vasopressin (Katusic et al, 1984)
Angiotensin II (Toda, 1984)
Oxytocin (Katusic et al, 1986)
(3 agonists (Carvalho et al, 1987)
Vasoactive Intestinal Peptide (Thorn et al, 1987)
Endothelin (Cocks et al, 1989)
Platelet Activating Factor (Chiba et al, 1990)
CGRP (Samuelson & Jernbeck, 1991)
Adrenomedullin (Hirata et al, 1995)
Endothelium dependent vasoconstrictors
Thrombin (De Mey & Vanhoutte, 1982)
Arachidonic Acid (De Mey A Vanhoutte, 1982)
Serotonin (Lamping et al, 1985)
Acetylcholine (Luscher & Vanhoutte, 1986)
a-agonists (Usui et al, 1987)
Neuropeptide Y (Daly & Hieble, 1987)
ADP/ATP (Shirahase et al, 1988)
Angiotensin II (Manabe et al, 1989)
Histamine (Rosenblum et al, 1990)
Somatostatin (Shirahase et al, 1993)
Platelet Activating Factor (Gao et al, 1995)
Substance P (Shirahase et al, 1995)
Endothelin (Taddei & Vanhoutte, 1993)
Urotensin-II (Ames etal, 1999)
PDGF = platelet-derived growth factor; ADP = adenosine diphosphate; ATP =
adenosine triphosphate; CGRP = calcitonin gene-related peptide; AMP = adenosine
monophosphate; PACAP = pituitary adenylate cyclase-activating polypeptide
Endothelium independent vasoconstrictors
Thrombin (Ku, 1982)
Serotonin (Cocks & Angus, 1983)
a-agonists (Cocks & Angus, 1983)
Acetylcholine (Griffith et al, 1984)
Histamine (Griffith et al, 1984)
Angiotensin II (Lamping et al, 1985)
Vasopressin (Katusic et al, 1986)
Oxytocin (Katusic et al, 1986)
Neuropeptide Y (Pernow & Lundberg, 1988)
Substance P (Beny & Brunet, 1988)
ArachidonicAcid(Boulanger&Vanhoutte,1993)
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Table 1.2 Endothelium derived relaxing factors & contracting factors
Endothelium derived relaxing factors
Nitric oxide (Palmer et al, 1987)
Prostacyclin (Weksler et al, 1977)
"Endothelium Derived Hyperpolarising Factor" (Komori et al, 1988)
FOR AGAINST
ammonium ions ? not (Feletou et al, 1989)
hydrogen peroxide ? not (Beny & von der Weid, 1991)
EETs ? (Campbell et al, 1996) or not ? (Zygmunt et al, 1996)
Anandamide ? (Randall et al, 1996) or not ? (Plane et al, 1997)
C-type natriuretic peptide ? probably not (Barton et al, 1998)
K+ ions ? (Edwards et al, 1998)
Endothelium derived contracting factors
Endothelin-1 (Yanagisawa et al, 1988)
Thromboxane (Ingerman-Wojenski et at, 1981)
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Table 1.3 Conditions associated with endothelial dysfunction
Hypertension (Winquist etal, 1984)
Diabetes mellitus (Oyama et al, 1986)
Hyperlipidaemia (Verbeuren et al, 1986)
Atherosclerosis (Ludmer et al, 1986)
Ageing (Soltis, 1987)
Heart failure (Kaiser et al, 1989)
Endotoxaemia (Siegfried et al, 1992)
Smoking (Celermajer et al, 1993)
Cyclosporin therapy (Gallego et al, 1993)
Hyperhomocystinaemia (Celermajer et al, 1993)
Renal failure (Nakayama et al, 1994)
Liver cirrhosis (Ferro et al, 1996)
Table 1.4 The family of angiotensins
Angiotensin 1 = Angiotensin-(l-lO) = Asp Arg Val Tyr He His Pro Phe His Leu
Angiotensin^1-9) = Asp Arg Val Tyr lie His Pro Phe His
Angiotensin II = Angiotensin^ 1-8) = Asp Arg Val Tyr He His Pro Phe
Angiotensin^ 1-7) = Asp Arg Val Tyr He His Pro
Angiotensin-(l-6) = Asp Arg Val Tyr He His
Angiotensin^ 1-5) = Asp Arg Val Tyr He
Angiotensin^ 1 -4) = Asp Arg Val Tyr
Angiotensin-(2-10) = Arg Val Tyr He His Pro Phe His Leu
Angiotensin-(2-9) = Arg Val Tyr He His Pro Phe His
Angiotensin III = Angiotensin-(2-8) = Arg Val Tyr He His Pro Phe
Angiotensin-(2-7) = Arg Val Tyr He His Pro
Angiotensin-(2-6) = Arg Val Tyr He His
Angiotensin-(2-5) = Arg Val Tyr lie
Angiotensin IV = Angiotensin-(3-8) = Val Tyr lie His Pro Phe
Angiotensin-(3-7) = Val Tyr lie His Pro
Angiotensin-(4-8) = Tyr lie His Pro Phe
Angiotensin-(5-8) = He His Pro Phe
Bradykinin (for comparison) = Arg Pro Pro Gly Phe Ser Pro Phe Arg
Substance P (for comparison) =Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met
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Table 1.5 The family of angiotensin receptors (<£ theirpreferred ligands)
Angiotensin II type 1 (ATI) receptor {Angiotensins II & III)
AT IA receptor
AT I B receptor
AT1C receptor ? = AT3 receptor ?
Angiotensin II type 2 (AT2) receptor {Angiotensins II & III)
Angiotensin II type 3 (AT3) receptor ? = AT1C receptor ?
Angiotensin II type 4 (AT4) receptor {Angiotensins III, IV& 1-7)
Angiotensin^I-7) receptor {Angiotensin 1-7)
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Methods
2.1 Introduction
We chose to use the technique of venous occlusion plethysmography for
measurement of forearm blood flow (and forearm venous capacitance) in patients with
heart failure. We were therefore examining clinical pharmacology in humans rather
than in animals. Findings in humans are inherently more important than findings in
animals as it is unpredictable to what extent responses may differ between the two,
and generally it is humans we are interested in treating, more than animals. We were
also examining clinical pharmacology in vivo rather than in vitro. Findings in vivo are
inherently more important than findings in vitro, as it is unpredictable to what extent
specimen preparation may alter "normal" physiology and pathophysiology (just as
Furchgott & Zawadzki discovered when they realised that vasodilation to
acetylcholine was endothelium-dependent). We were also examining clinical
pharmacology in patients with heart failure rather than some model of heart failure.
Findings in patients with heart failure are more important than findings in models of
heart failure, as, despite the prevalence of heart failure, efforts have yet to yield a
really convincing model of heart failure which replicates it in all its complexity. We
were also examining clinical pharmacology in a single vascular bed rather than at the
whole body level. Whilst testing potentially untried substances it is obviously safer to
do so with small doses at the local level rather than with larger doses at the systemic
level. Apart from this, there is the fact that different vascular beds may very well
differ in their response to any given substance (presumably due to phenotypic
differences in gene expression) and may cancel each other out, or at least make
systemic effects very much more difficult to interpret. Although systemic studies are
therefore important, local studies (preferably in more than one vascular bed) are just
as important, and probably a necessary preliminary to the former (especially when
testing potentially untried substances).
2.2 Background
Plethysmography is the method of measuring variations in the size of parts of
the body (from Greek, plethynein to increase), and venous occlusion plethysmography
is the method of measuring arterial inflow by measuring the increases in size of parts
of the body which result from occlusion of venous outflow. It will be immediately
obvious that the method is most easily applied to appendages such as limbs or digits,
and indeed, the method is most often used for measurement of blood flow in the calf,
the thigh, or as in this case, the forearm. When first developed, the technique
required the limb in question to be encased in a box containing air or water, so that
the displacement of air or water, or changes in pressure, could be measured to give
the change in volume of the limb in question (Whitney et al, 1953). This technique
was obviously extremely cumbersome and subject to interference from multiple
sources, and hence difficult for the investigator to manage and equally difficult for the
subject to endure. The development of a strain gauge which could measure changes
in size more directly and more easily transformed the technique and made it much
more widely applicable (Hokanson et at', 1975). Originally this took the form of a
hollow loop of elastic filled with liquid mercury, the electrical conductance of which
depended on its degree of distension (a variety of piezoelectric effect). This is simply
looped around the limb in question and a voltage plethysmograph measures the
minute changes in resistance which can be calibrated to equate with changes in limb
size. Over subsequent years the strain gauge has evolved into a hollow loop of
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Silastic (for durability) filled with a liquid alloy of indium and gallium (for safety), but
the principle is exactly the same.
2.3 Ward set-up
For measurement of forearm blood flow by venous occlusion plethysmography
the subject attends having abstained from alcohol, caffeine and tobacco for 24 hours,
and from food for 6 hours, and having emptied the bladder. It is obviously important
that the subject has abstained from any potentially vasoactive stimulants, but it is also
important that digestion is not active, as this could divert blood from the limbs to the
gastro-intestinal tract. For this reason, all our studies were conducted in the early
afternoon, with subjects having breakfasted, but having abstained from lunch. Studies
can be quite time-consuming, and it is important that the patient is as comfortable as
possible. Nothing upsets delicate haemodynamic measurements like an uncomfortably
full bladder (quite apart from the fact that it may lead to early termination of the
study, and a loss of co-operation for future studies). The subject is accommodated in
a quiet research ward maintained at a constant temperature of 23-25°C. It is
important that the ward is quiet and that its peace is not disturbed, as any sudden
interruptions can have surprisingly significant effects on blood flow. It is also
important that the ward is a comfortable temperature and that that temperature is
maintained, as any variations in temperature will affect blood flow (generally increases
in temperature cause vasodilation and decreases in temperature cause
vasoconstriction). The subject or patient lies on a comfortable bed for at least 20
minutes before any drug infusion while haemodynamics adjust to the supine position.
It is important that the subject or patient is as comfortable as possible, as studies can
be quite time-consuming, and it is obviously important that the results of the study are
not confounded by unstable baseline haemodynamics.
2.4 Subject set-up
The subject's forearms are both supported on pillows, cushions or foam pads
so that they are at or above the level of the right atrium. This assists venous outflow
by means of gravity, so that after the cessation of venous occlusion the forearm
quickly returns to normal, prior to the next measurement. Pressure cuffs are applied
to both upper arms (Hokanson SC10, PMS Instruments, Maidenhead, Berkshire) for
venous occlusion (~40mmHg), and to both wrists (Hokanson SC5, PMS Instruments)
for arterial occlusion (~220mmHg) and isolation of the hand circulation. The reason
for this is that whilst the forearm circulation is mostly muscle perfusion, the hand
circulation is mostly skin perfusion, and behaves differently, and indeed, somewhat
unpredictably. The pressure cuffs are connected to a pair of rapid cuff inflators
(Hokanson E20, PMS Instruments) supplied by a commercially available air source
(Hokanson AG 101, PMS Instruments). Indium/gallium-in-Silastic strain gauges
(Hokanson forearm set, PMS Instruments) of an appropriate size are applied to the
widest aspect of each forearm and connected to a voltage plethysmograph (Hokanson
plethysmograph, PMS Instruments).
2.5 Intrabrachial cannulation
After local anaesthesia with 1% lidocaine (Phoenix Pharma, Gloucester), a 27-
gauge steel needle (Terumo Medical Corporation, Tokyo, Japan) is inserted into the
brachial artery (non-dominant, to minimise the consequences in case of the very slight
risk of complications), and connected to a constant rate infusion pump (IVAC PI000,
Alaris Medical Systems, San Diego, California, USA) via a 16-gauge epidural catheter
(Portex Limited, Hythe, Kent). Physiological saline solution (0.9%, Baxter
Healthcare Corporation, USA) is infused at 1 ml/min for at least 20 minutes before
any drug infusion. Forearm blood flow often increases and occasionally decreases in
the infused arm after insertion of the intrabrachial needle, and it is obviously important
that blood flow equilibrates first, so that changes in baseline blood flow do not
confound the results of the study.
2.6 Measurement of blood flow
To measure blood flow, the wrist cuffs are inflated to supra-systolic pressure
(~220mmHg) for ~2Vi minutes while the upper arm cuffs are repeatedly inflated to
venous occlusion pressure (~40mmHg) for -12 seconds and deflated for ~4 seconds.
This gives about 9 separate plethysmographic recordings for each arm. The first
minute or so of each set of recordings needs to be ignored as forearm blood flow-
adjusts to wrist arterial occlusion. This leaves the last 5 recordings to be used for
further analysis (Figure 2.1). Output from the voltage plethysmograph is transferred
via an analog-to-digital converter (MacLab 4e, AD Instruments, Hampstead, London)
to a personal computer (PowerMac, Apple Computer Incorporated, USA). The data
is plotted using Chart software (Chart version 3.2.8; AD Instruments) and analysed
using Excel software (Excel version 7.0, Microsoft Corporation, USA).
2.7 Analysis
Plethysmographic recording gives an upward slope during venous occlusion,
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the gradient of which is proportional to the rate of blood flow. For the purposes of
our studies, we were interested in the effect of drug infusion in the non-dominant arm.
The ratio of the gradient of the slope of plethysmography recording in the infused
arm to the gradient of the slope of plethysmographic recording in the non-infused arm
is therefore equivalent to the ratio of blood flow between the two arms. The mean of
the 5 last plethysmographic recordings is used to reduce the influence of background
variation and improve the "signafnoise ratio". The effect of drug infusion is
expressed in terms of percentage increase or decrease in blood flow, and is calculated
by dividing the ratio of blood flow between the two arms during drug infusion by the
ratio of blood flow between the two arms at baseline (Table 2.1). Provided blood
pressure remains constant, increases in blood flow represent vasodilation and
decreases in blood flow represent vasoconstriction. It is possible to use blood
pressure to calculate forearm vascular resistance, but this gives an arbitrary sense of
objectivity, and is not recommended. It is also possible to calibrate the equipment so
that blood flow in one or both arms can be expressed in absolute units if required.
This means preserving the denominator of time and expressing the gradient in mis per
lOOmls of forearm volume per minute by comparison with a 1% calibration spike
(which obviously represents 1 ml per lOOmls of forearm volume).
2.8 Blood flow results
The above method is less complicated than it appears. Forearm blood flow, as
we have mentioned, is very sensitive to multiple influences such as noise, temperature
and discomfort of any sort. Whilst it is still worthwhile controlling these influences,
as described above, the method has the strong attraction of factoring all of these
influences out of the equation. In using the ratio of blood flow between the two arms
to examine the effect of drug infusion, we are effectively using the non-infused arm as
a contemporaneous control. All extraneous influences will influence both arms
equally, so that the only difference between the two arms is the difference between
drug infusion and no drug infusion. In addition, the results are adjusted to take
account of any differences at baseline, so that any effect of needle insertion or saline
infusion is also factored out of the equation. In a set-up similar to our own, the
technique has been shown to be highly reproducible, with an intra-subject variability
of 19% between studies (Petrie et al, 1998).
2.9 Alternative methods of blood flow measurement
Given the attractions of this method, it is hardly surprising that it is regarded
as the "gold standard" of in vivo vasomotor assessment (Roberts et al, 1986;
Benjamin et al, 1995; Petrie et al, 1998), and over 700 papers using the method have
been published over the last 30 years or so. The principle alternatives that have been
explored are direct intravascular measurement of blood flow, and external ultrasonic
measurement of blood flow. The first of these has the attraction that it is seems to be
more direct, but it has the considerable disadvantage that it requires much larger more
complex intravascular catheters and is therefore more invasive (and potentially more
risky). The second has the attraction that it seems to be less invasive, but it has the
disadvantage that it cannot measure blood flow directly. Instead, it depends on the
measurement of blood flow velocity and arterial diameter individually (by separate
ultrasound modalities, 2D and Doppler), and the product of the two to give a measure
of volumetric blood flow. This means that two separate sources of error are
multiplied together to give an increased margin of error. It is remarkable how often
papers using this method report their results selectively (perhaps because their
hypothesis is sustained by one or two out of the measures of blood flow velocity,
arterial diameter and volumetric blood flow, but not by the others).
2.10 Measurement of venous capacitance
Venous occlusion plethysmography can also be used to provide a measure of
venous capacitance, which is a measure of venous distensibility or venous tone. If the
arm cuffs are inflated to venous occlusion pressure and not deflated, forearm size will
continue to increase until venous pressure comes to equal the venous occlusion
pressure (after which point, venous outflow will resume). Using exactly the same
ward set-up and subject set-up described above, the wrist cuffs are inflated to arterial
occlusion pressure. Once the plethysmographic recordings have stabilised, after
approximately 15 seconds, the upper arm cuffs are inflated to venous occlusion
pressure. Once the plethysmographic recordings have plateaued, after approximately
2 minutes, the upper arm cuffs are deflated. Once the plethysmographic recordings
have returned to baseline again, after approximately 15 seconds, the wrist cuffs are
deflated. The difference between the peak plethysmographic recording and baseline
(which can be taken as a mean of the baseline just before venous occlusion and the
plateau following relief of venous occlusion) is a measure of venous distensibility, i.e.,
venous capacitance. This can be expressed in mis per 100 mis of forearm volume by
comparison with a 1% calibration spike on the plethysmograph (which obviously
represents 1 ml per 100 mis of forearm volume).
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2.11 Pulse and blood pressure measurement
Pulse and blood pressure were recorded at regular intervals in all studies by
either a manual sphygmomanometer or a semi-automatic sphygmomanometer. This
was either applied to the dominant arm over the venous occlusion cuff or to the calf
on the same side. It is obviously important not measure blood pressure
simultaneously with plethysmography recordings. Some of the protocols employed
allowed time for measurement ofblood pressure in the arm between plethysmographic
recordings. Some protocols did not leave enough time for this, however, and in these
cases the calf was used. We therefore took care to make sure that there was at least
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Figure 2.2 Schematic representation of plethysmographic recordings (venous
capacitance measurement)
0s 15s 135s 180s
wrist arm arm wrist
cuff cuff cuff cuff
inflation inflation deflation deflation
0s 15s 135s 180s
wrist arm arm wrist
cuff cuff cuff cuff
inflation inflation deflation deflation
Venous capacitance (right arm) = dvrp - ((dvrbl + dvrb2) 2)
Venous capacitance (left arm) = dvlp - ((dvlb l + dvlb2) 2)
which both need to be divided by the height of a 1% calibration spike (which
corresponds to 1 ml/100ml forearm volume) to give venous capacitance in mis per
1 OOmls forearm volume
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Effect of arachidonic acid in heart failure
3.1 Introduction
Despite over 30 years' study, it remains unclear whether or not low-dose
aspirin has clinically significant vascular effects, in addition to its antiplatelet effects.
On the one hand, it has been suggested that aspirin is not safe in heart failure (Cleland
et al, 1995), or that aspirin might counteract the beneficial effects of angiotensin
converting enzyme (ACE) inhibitors in heart failure (Hall et al, 1992). On the other
hand, it has been suggested that aspirin might improve endothelial dysfunction
(Husain et al, 1998; Noon et al, 1998), or that aspirin and ACE inhibitors might have
similar modes of action (Jeserich et al, 1995). It is important to know the truth, given
the widespread use of aspirin in patients with heart failure due to ischaemic heart
disease. The absence of any obvious haemodynamic effect of aspirin on its own has
necessitated examination of more complex interactions. Unfortunately these studies
have failed to provide a consistent answer (Hall et al, 1992; Fitzgerald et al, 1983;
Masotti et al, 1979; Heavey et al, 1985). The vascular effects of aspirin might be
clarified by selective stimulation of vascular endothelium at the point where aspirin
exerts its effect.
Aspirin exerts its effects by inhibition of cyclooxygenase, the first enzyme in
the pathway that converts arachidonic acid to prostaglandin (Vane et al, 1971).
Arachidonic acid is liberated by hydrolysis of phospholipid in the cell membrane by
phospholipase A2 (Gelb et al, 1994). The effect of exogenous aspirin on endogenous
cyclooxygenase might therefore be effectively interrogated by examination of the
effect of exogenous aspirin on exogenous arachidonic acid. Arachidonic acid has
been shown to be vasodilating in the preconstricted dorsal hand vein of healthy
humans in vivo (Bhagat et al, 1995), but has not otherwise been studied in humans, or
at all in heart failure. Furthermore, arachidonic acid has also been shown to have
quite opposite effects in different tissues (Sessa et at, 1990; Pagano et al, 1991), in
different species (Sessa et al, 1990; Oyekan et al, 1991) or under different conditions
(Oyekan et al, 1991) in animal studies. We therefore sought to validate the effects of
arachidonic acid in a different vascular bed in humans in vivo, to examine the effects
of heart failure on this pathway, and to examine the effects of clinically relevant doses
of aspirin on this pathway in heart failure. It has been suggested that lower doses of
aspirin may be more "vascular-sparing" than higher doses (Masotti et at, 1979). We
were keen to examine this in humans rather than animals, in vivo rather than in vitro,
and with real responses of clinically significant blood vessels.
3.2 Methods
3.2.1 Subjects
The study was conducted with the approval of the West Ethics Committee and
all subjects and patients gave written informed consent. A group of 10 healthy
volunteers with no medical conditions and on no medications was studied (6 male/4
female; mean age 30+4 years). A number of pilot and dose-ranging studies were also
conducted in these subjects, in order to establish the safety of intrabrachial
arachidonic acid and an appropriate dose for demonstration of its arterial vasomotor
effects (if any).
3.2.2 Patients
Fifteen patients with chronic heart failure secondary to left ventricular systolic
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dysfunction confirmed by echocardiography were studied (left ventricular ejection
fraction <40%). All patients were clinically stable on constant medication for 3
months, with no peripheral oedema or pulmonary congestion, and no uncontrolled
hypertension, hypercholesterolaemia or diabetes mellitus. All patients were treated
with an ACE inhibitor (enalapril lOmg bd in the majority). All medication apart from
aspirin was constant throughout the study. Patient characteristics are summarised in
Table 3.1.
3.2.3 Treatment
Healthy volunteers were studied having abstained from all aspirin for 14 days,
from alcohol, caffeine and tobacco for 24 hours, and from food for 6 hours. Patients
were all studied on three separate occasions after 14 days of aspirin Omg daily; after
14 days of aspirin 75mg daily; and after 14 days of aspirin 300mg daily (having
abstained from all other aspirin during that time). The order of study was varied
although not formally randomised (the majority were habitually on aspirin 75mg and
were therefore studied in the order: 75mg; Omg; 300mg). Patients took their usual
medications including aspirin as directed 6 hours before attendance on the day of
study, having abstained from alcohol, food, caffeine and tobacco as above. The study
design is summarised in Figure 3.1.
3.2.4 Measurements
Forearm blood flow was measured by the technique of venous occlusion
plethysmography as described in chapter 2. Plethysmographic recordings were made
every 5 minutes, and pulse and blood pressure were manually recorded in the non-
infused arm every 10 minutes.
3.2.5 Drugs
Sodium arachidonate (5 mg per vial) stored under nitrogen was obtained from
Sigma. Vials were stored at -20°C, and a single vial was used for each study, used
within 2 hours and discarded thereafter. Sodium arachidonate (5mg) was dissolved in
154pl absolute alcohol, filtered through a lpm filter, and diluted with physiological
saline to a final concentration to be infused at 1 ml/min. In the first few pilot studies
the doses chosen were 200 pmol/min, 2 nmol/min and 20 nmol/min (as in the vein
studies of Bhagat et al, 1995), each for 20 minutes. When further dose-ranging
studies were required the doses arbitrarily chosen were 20 nmol/min for 60 minutes,
and 83, 112, 116, 150, 200 and 225 nmol/min each for 30 minutes. The dose finally
settled on was 112 nmol/min for 45 minutes (the total dose was therefore 5pmol).
3.2.6 Data analysis
All results are expressed as mean values with standard errors. Because
repeated serial measurements were made in every study, comparison between studies
was performed using summary measures, i.e., mean response over the 45 minute
infusion period and peak response during the 45 minute infusion period, to avoid
making multiple comparisons on dependent variables (Matthews et at, 1990).
Summary measures were then compared using two-tailed paired t tests with
Bonferroni adjustments as required for multiple comparisons. Differences were




Local infusion of arachidonic acid caused no adverse or systemic effects, and
subjects and patients did not report any discomfort. Pulse rate (Figure 3.2), blood
pressure (Figure 3.3), and forearm blood flow in the non-infused forearm did not
change significantly on any of the studies, and there were no significant differences in
baseline pulse rate (Figure 3.2), blood pressure (Figure 3.3) or forearm blood flow
between any of the studies.
3.3.2 Pilot and dose-ranging studies
The initial three studies were closely modelled after the vein studies of Bhagat
et al (1995), as these were the only studies with arachidonic acid in vivo in humans in
the literature at the time. Arachidonic acid was therefore infused at 200 pmol/min, 2
nmol/min and 20 nmol/min, albeit for 20 minutes each rather than the 5 minutes each
of the earlier study. When there was no obvious effect at any of these doses, we tried
a 60 minute infusion of 20 nmol/min in three further studies. When there was no
obvious effect of this either, we tried 30 minute infusions of 83, LI 2, 116, 150, 200
and 225 nmol/min. The lower three doses produced modest vasodilation, and the
higher three doses produced dramatic vasodilation, but in two out of the three cases,
this was complicated by occlusion of the intrabrachial cannula. We therefore settled
on a 45 minute infusion of 112 nmol/min as a compromise. This meant that the total
dose delivered was 5000nmol, which compares favourably with the total dose of
lOOnmol delivered in the highest dose vein study (since the rate of blood flow in the
brachial artery is approximately 50 times that in the dorsal hand vein it is necessary to
deliver up to 50 times the dose of any drug to have an equipotent effect).
3.3.3 Effect of arachidonic acid infusion
Local infusion of 112 nmol/min of arachidonic acid for 45 minutes produced
progressive and incremental forearm vasodilation throughout the infusion period.
Figure 3.4 shows the effects of 112 nmol/min of arachidonic acid for 45 minutes in
healthy volunteers. The mean response was a dilatation of 33+6% and the peak
response was a dilatation of 64±10%.
3.3.4 Effect of heart failure on response to arachidonic acid
There was no significant difference in vasodilation to arachidonic acid between
healthy volunteers and patients with heart failure with no aspirin pre-treatment.
Neither mean vasodilation (33±6% versus 28+7%) (Figure 3.5) nor peak vasodilation
(64+10% versus 55±11%) (Figure 3.6) was significantly different.
3.3.5 Effect of aspirin on response to arachidonic acid infusion
Mean vasodilation was reduced by 55% following pre-treatment with 75mg
aspirin (13±8% versus 28±7%) and by 59% with 300mg aspirin (12+7% versus
28+7%) (Figure 3.5). Peak vasodilation was reduced by 35% following pre-treatment
with 75mg aspirin (36±12% versus 55±11%) and by 45% with 300mg aspirin (30±9%
versus 55+11%) (Figure 3.6). The differences between no aspirin pre-treatment and
aspirin pre-treatment were significant regardless of dose, and there was no significant
difference between the two different doses of aspirin.
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3.4 Discussion
We have shown that arachidonic acid causes vasodilation in the forearm of
humans in vivo, that this response is unaffected by heart failure, that in patients with
heart failure this response is inhibited by aspirin, and that this inhibition is apparent
with a dose as low as 75mg once daily. The first of these findings is novel but
perhaps not unexpected, the second is novel and quite unexpected, the third is novel
although very much as expected, and the fourth is novel, quite unexpected and has
potential implications for vascular biology (and even more importantly for clinical
medicine).
3.4.1 Safety of arachidonic acid
We have no way of knowing why the higher doses of arachidonic acid were
complicated by occlusion of the intrabrachial cannula. Obviously we can't help
suspecting the possibility of platelet activation and aggregation at the needle tip.
Although the concentrations of arachidonic acid used would have been enough to
cause platelet activation in vitro, we had hoped to avoid any possibility of this in vivo
because of the rate ofblood flow within the brachial artery and rapid dissipation of the
infused solution. We avoided the use of these higher doses in further studies.
3.4.2 Vasodilation by arachidonic acid
This is the first demonstration that arachidonic acid is vasodilating in arteries
in humans in vivo. Although we had no control infusion for arachidonic acid and it is
therefore possible that the effect was due to vehicle (i.e., a very low concentration of
ethanol), this is unlikely, as ethanol is well-recognised to be a vasoconstrictor when
directly applied to blood vessels (Hayes et al, 1988). As previously noted, it has
previously been demonstrated that arachidonic acid is vasodilating in veins in humans
in vivo (Bhagat et al, 1995). As previously noted also, it has been demonstrated that
the response to arachidonic acid is extremely heterogeneous between different tissues,
different species and different conditions in animals (Sessa el al, 1990; Pagano et al,
1991; Oyekan et al, 1991). The demonstration that arachidonic acid is indeed
vasodilating in arteries as well as in veins confirms the potential importance of this
pathway in humans in vivo. It also suggests the potential importance of this pathway
in heart failure and the potential importance of modulation of this pathway in this
syndrome. Notwithstanding, it is important to remember that the effects of
exogenous administration of an agonist do not necessarily tell us very much about the
endogenous activity of the same agonist, if any.
3.4.3 Effect of heart failure on response to arachidonic acid
It is surprising that the response to arachidonic acid appeared to be so little
different between healthy volunteers and patients with heart failure, as it has
previously been reported that cyclooxygenase gene expression is down-regulated in
heart failure (Smith et al, 1996). There is no doubt that our patients had clinically
well-characterised heart failure, but it would have been desirable to have had more
objective information about them at baseline, such as an assessment of their degree of
neuroendocrine activation. It would clearly have been preferable to have age-matched
controls, but given that there was so little difference between our controls and our
patients with heart failure, it seems unlikely that age-matched controls would have
been much different from either, but we cannot know this. Indeed, given that there
was such an age-difference, it is perhaps even less likely that the small non-significant
difference shown was due to heart failure. It is equally possible that there is some
deficiency in heart failure patients which was compensated for by their ACE inhibitor
treatment, but we cannot know this either. It is clear that there is some heterogeneity
of vasodilator responses in heart failure. It is clear that the response to acetylcholine
or methacholine is reduced and that the response to nitroglycerin or sodium
nitroprusside is not (Kubo et al, 1991). At the same time, there is some controversy
surrounding the response to substance P (Hirooka et al, 1992; Lindsay el al, 1996),
and surprisingly little information on the response to bradykinin (Cheng et al, 1998;
Su et al, 1998). Our findings suggest that at least some aspects of vascular
prostanoid production and activity may be unimpaired in patients with treated heart
failure, but this is clearly deserving of further study.
3.4.4 Effect of aspirin on response to arachidonic acid
The most striking finding of our study was that vasodilation to arachidonic
acid was significantly blocked (by over half) by a dose of aspirin as small as 75mg
once daily in patients with heart failure. It would have been preferable to make this
comparison on the basis of randomised double-blind treatment, but the magnitude of
the reduction makes it unlikely that it is simply a result of bias. This contradicts the
widely held view that such small doses of aspirin can be regarded as "platelet-specific"
or "vascular-sparing". In fact, this may be consistent with the majority of previous
studies in this field, but it is much more clinically relevant because we chose to
examine the chronic (14-day) effects of the doses in common use for
cardioprotection, something which previous studies have failed to do.
3.4.5 Comparison with effects of aspirin on prostacyclin
The earliest studies with any relevance to the vascular effects of aspirin
measured the levels of thromboxane and prostacyclin, focusing on preserved levels of
prostacyclin as a measure of preserved endothelial cyclooxygenase activity. The
results of such studies are not particularly consistent. At least three studies have
shown preserved prostacyclin, with a single dose below 75mg (Hanley et al, 1981),
with 7 days of less than 75mg (Patrignani et al, 1982), and with a single dose ofwell
above 75mg (Masotti et al, 1979). At the same time two studies have shown
suppressed prostacyclin with 7 days of doses well below 75mg (Fitzgerald et al, 1983;
Weksler et al, 1985). So far as it is possible to collate these results, there appears to
be a threshold for suppression of prostacyclin by aspirin which lies somewhere
between 20mg and 250mg, with some evidence of a lower threshold for repeated
doses than for single doses. The results of such studies cannot really be taken as
evidence of an overall vascular effect of aspirin one way or the other, because they did
not measure any sort of vascular activity directly. Furthermore, none of these studies
was conducted in patients with heart failure, all were in normals, hypertensives or
coronary patients.
3.4.6 Comparison with effects of aspirin on bradykinin
More recently, a number of studies have focused on the effect of aspirin on the
response to bradykinin. Bradykinin is a potent vasodilator in its own right, which
clearly also stimulates prostacyclin production (Barrow et al, 1986). There have been
a number of studies that have looked at the effects of aspirin on the response to
bradykinin, both in terms of vasodilation and in terms of prostacyclin production. The
57
results of these studies have been a bit more consistent. Three studied the effect of a
single dose of 600mg and showed blockade of prostacyclin but not vasodilation
(Heavey et al, 1985), no effect on vasodilation (Benjamin et al, 1989), and blockade
of prostacyclin (Ritter et al, 1989), respectively. Two more studied the effect of
repeated doses of 75mg, for 4 days (Clarke et a/, 1991), and 14 days (Keimowitz et
al, 1993), and both showed blockade of prostacyclin. Despite the consistency of
these results, the obvious discrepancy between suppression of prostacyclin production
and vasodilation calls into question the relevance of prostacyclin production to the
vasodilator effects ofbradykinin, or indeed to the vasodilator effects of any mediator.
3,4.7 Comparison with effects of aspirin on ACE inhibitors
Most recently a number of studies have attempted to look directly at the
interaction between aspirin and ACE inhibitors and again the results have been fairly
inconsistent. A single dose of aspirin 350mg counteracted some but not all of the
haemodynamic effects of a single dose of enalapril lOmg (Hall et al, 1992). A single
dose of aspirin 236mg had no effect on the haemodynamic effects of a single dose of
captopril 25mg (van Wijngaarden et al, 1994). A single dose of aspirin 500mg
prevented the apparent improvement in endothelial function from intra-arterial
enalaprilat (Nakamura et al, 1994). Aspirin 250mg had no effect on the
neurohormonal or haemodynamic effects of enalapril 5-10mg either overnight or after
4 weeks (Baur et al, 1995). Aspirin 325mg od counteracted the 15 day improvement
in pulmonary diffusion from enalapril lOmg bd (Guazzi et al, 1997). Aspirin 325mg
od for 7 days (but not ticlopidine) counteracted some but not all of the haemodynamic
effects of a single dose of enalapril lOmg (Spaulding et al, 1998). Neither aspirin nor
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ifetroban (a thromboxane receptor antagonist) had any effect on the effect of 6 weeks
of enalapril on forearm blood flow (Katz el al, 1999).
3.4.8 Effects of aspirin on arachidonic acid
The only other experience of the effect of aspirin on vasodilation stimulated by
exogenous arachidonic acid in humans was reported by Bhagat el al (1995). These
authors found that a single large dose of oral aspirin (lg) inhibited arachidonic acid-
induced venodilation 2 hours later, but low-dose aspirin (75mg) did not. Whether the
difference from our results reflects a difference in the sensitivity of arteries and veins,
a difference between acute and chronic dosing, a difference between healthy subjects
and heart failure, an interaction with ACE inhibitors, or some combination of these
factors, we do not know. Any of these considerations would be ripe for further
investigation.
3.4.9 Summary
We chose to look at the effects of chronic daily dosing with aspirin, and we
chose to compare the effects of the highest dose in common use for cardioprotection
(300mg) with the lowest dose in common use for cardioprotection (75mg). Whilst
our findings really only apply to the time window in which they were conducted (6-8
hours after the last dose of aspirin) this implies a significant portion of the day, (a
quarter to a third at the very least), during which even very low dose aspirin has
detectable potentially detrimental effects. There are lower doses of aspirin which
achieve adequate inhibition of platelet cyclooxygenase (Patrono et al, 1985), and
which might not affect vascular arachidonic acid metabolism. There are also other
formulations of aspirin (Clarke et al, 1991), or routes of administration of aspirin
(Keimowitz et al, 1993; Pedersen et al, 1984; Cerletti et al, 1986), which might do the
same. None of these is in routine clinical practice, however, and we sought to make
our findings as clinically relevant as possible. Although it is possible that fourteen
days is not long enough to observe the full vascular profile of aspirin (which might be
more complex), it is longer than the treatment in any other comparable study. Our
findings lead us to suspect that the reason that vasodilation was so sensitive to even a
very low dose of aspirin may be because of the length of treatment in our study.
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Table 3.1 Patient Characteristics
Patient Characteristic
Sex, n 13M/2F
Age, y (mean±SD) 69±7
Primary diagnosis IHD, n 14
IDC, n 1
NYHA functional class II, n 11
III, n 4
LVEF, % (mean±SD) 21+7
Current smoker, n 1
On ACE inhibitor, n 15





Beta blocker, n 5




IHD = ischaemic heart disease; IDC = idiopathic dilated cardiomyopathy; NYHA
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Figure 3.2 Heart rate during arachidonic acid infusion in 15 patients
according to aspirin pre-treatment (p=ns for all comparisons)














Figure 3.3 Mean blood pressure during arachidonic acid infusion in 15















Figure 3.4 Effect of brachial artery infusion of arachidonic acid 112
nmol/min for 45 minutes in 10 controls
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Figure 3.5 Mean vasodilation according to aspirin pre-treatment (control
versus aspirin Omg, p=ns; aspirin 75mg versus aspirin Omg, p=.0025; aspirin
300mg versus aspirin Omg, p=.021; aspirin 75ing versus aspirin 300ing, p=ns)
Control subjects CHF patients
(aspirin Omg)
CHF patients CHF patients
(aspirin 75mg) (aspirin 300mg)
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Figure 3.6 Peak vasodilation according to aspirin pre-treatment (control
versus aspirin Oing, p=ns; aspirin 75mg versus aspirin Oing, p=.077; aspirin
3G0mg versus aspirin Omg, p=.006; aspirin 75ing versus aspirin 300mg, p=ns)
Control subjects CHF patients
(aspirin Omg)
CHF patients CHF patients
(aspirin 75mg) (aspirin 300mg)
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Interaction of aspirin and furosemide in heart failure
4.1 Introduction
Intravenous furosemide is commonly administered to patients with acute heart
failure to relieve pulmonary congestion through diuresis. However, it has long been
recognised that symptomatic relief occurs in these patients before diuresis has had
time to occur (Weinstein & Solis-Gil, 1966; Biagi & Bapat, 1967; Bhatia et al, 1969).
It has also long been recognised that this effect may be a consequence of a venodilator
effect which precedes the diuretic effect (Dikshit et al, 1973). It is fairly well-
established that the venodilator response to furosemide is inhibited by the
cyclooxygenase inhibitor indomethacin, so it is usually assumed that this venodilation
is brought about through the release of local prostanoids (Johnston et al, 1983;
Pickkers et al, 1997). Our hypothesis was that aspirin might also inhibit the acute
venodilator response to furosemide in patients with chronic heart failure. The present
study was designed to determine whether or not the doses of aspirin shown to block
the arterial vasodilator response to arachidonic acid in chapter 3 (75mg and 300mg
daily) also affect the venodilator response to furosemide. We also studied the
immediate venodilator response to sublingual glyceryl trinitrate (GTN) to set the
venodilator effect of furosemide in a more clinically familiar context.
4.2 Methods
4.2.1 Patients
The study was conducted with the approval of the West Ethics Committee and
all patients gave written informed consent. Eleven patients with chronic heart failure
secondary to left ventricular systolic dysfunction confirmed by echocardiography (left
ventricular ejection fraction <40%) were studied in each study. All patients were
clinically stable on constant medication for 3 months, with no peripheral oedema or
pulmonary congestion, and no uncontrolled hypertension, hypercholesterolaemia or
diabetes mellitus. All patients were treated with an ACE inhibitor (enalapril lOmg bd
in the majority). All medication apart from aspirin was constant throughout the first
study and all medication was constant in the second study. Patient characteristics for
the two studies are summarised in Table 4.1.
4.2.2 Randomisation
Patients in the first study were randomised to double-blind cross-over
treatment with aspirin 75mg for 14 days, aspirin 300mg for 14 days and paracetamol
120mg for 14 days (as a non-vasoactive placebo). At the end of each 14 day study
period, patients attended for venous occlusion plethysmography and the following day
crossed over to the next randomly assigned drug. During each 14 day period patients
abstained from all other aspirin, aspirin-containing or aspirin-like medications.
Patients took their usual medication including aspirin/paracetamol 6 hours before
attendance on the day of study. Patients abstained from alcohol, tobacco and caffeine
for 24 hours before each study and attended fasted for 6 hours. Patients were
instructed to withhold their diuretic therapy on the day of study, but to take all other
medication as normal. Patients in the second study were not randomised but were
invited to take their usual aspirin therapy as prescribed and were instructed to
withhold any nitrate therapy on the day of study, but to take all other medication as
normal. The study design is summarised in Figure 4.1.
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4.2.3 Treatment
In the first study, 20mg of furosemide (Antigen Pharmaceuticals, Rosecrea,
Co Tipperary, Ireland) was administered over the course of 30 seconds through a 20G
intravenous cannula (Biovalve, Vygon, USA) sited in the forearm. The cannula was
then flushed with a further 5ml of physiological saline solution (Baxter Healthcare
Corporation, USA). In the second study, 400pg of GTN (Lipha Pharmaceuticals,
France) was administered sublingually.
4.2.4 Measurements
Forearm blood flow and venous capacitance were measured in both arms by
the technique of venous occlusion plethysmography as described in chapter 2.
Plethysmography recordings were made at 5 minute intervals for 20 minutes before
furosemide/GTN administration and at 5 minute intervals for 20 minutes after
furosemide/GTN administration.. Pulse rate and blood pressure were recorded at 5
minute intervals throughout with a semi-automatic sphygmomanometer (Dinamap
Plus 8700; Johnson & Johnson, USA) and a leg cuffwrapped round the right calf.
4.2.5 Data analysis
All results are expressed as mean values with standard errors. Because
repeated serial measurements were made in every study, comparison between studies
was performed using a summary measure, i.e., mean response over the 20 minutes
following furosemide/GTN administration infusion, to avoid making multiple
comparisons on dependent variables (Matthews ei al, 1990). Summary measures
were then compared using two-tailed paired t tests. Differences were considered
significant at a value of p< 05.
4.3 Results
4.3.1 General effects
Furosemide and GTN administration caused no adverse or obvious systemic
effects, and patients did not report any discomfort. Pulse rate and blood pressure did
not change significantly during any of the studies. There were no significant
differences in baseline pulse rate, blood pressure, forearm blood flow or venous
capacitance between any of the studies.
4.3.2 Effect of furosemide/GTN on forearm blood flow
Forearm blood flow was not significantly affected by the administration of
intravenous furosemide on any of the three study days. Similarly, forearm blood flow
was not significantly affected by the administration of sublingual GTN.
4.3.3 Effect of furosemide/GTN on forearm venous capacitance
In the placebo study there was a 2.25±1.82% increase in forearm venous
capacitance after furosemide administration. In the aspirin 300mg study there was a
3.77±1.82% fall in venous capacitance after furosemide administration (p<0001
versus placebo). In the aspirin 75mg study there was a 1.24±1.67% fall in venous
capacitance after furosemide administration (p<01 versus placebo; p=ns versus
aspirin 300mg) (Figure 4.2). Glyceryl trinitrate caused a 2.11+1.91% increase in
forearm venous capacitance (Figure 4.3). This was not significantly different from the
increase observed after intravenous furosemide in the placebo study (p=0.07).
4.4 Discussion
Furosemide caused an increase in forearm venous capacitance in our patients.
This effect has not been described in patients with chronic heart failure before.
Previously venodilation has only been described in patient with acute heart failure
secondary to myocardial infarction (Dikshit et al, 1973) and salt depleted volunteers
(Bhatia et al, 1969; Johnson et al, 1983, 1984, 1985, 1986; Passmore et al, 1989).
Our data support the hypothesis that furosemide has a potentially beneficial
haemodynamic effect before diuresis has time to occur and effect any haemodynamic
change itself. In the absence of a control infusion for furosemide, however, we
cannot be absolutely certain that the effect of furosemide on its own was significant.
This is in marked contrast to the effect of aspirin on the response to furosemide,
which was controlled for.
4.4.1 Prostaglandins and venodilation
A daily dose of 75mg and 300mg of the cyclooxygenase inhibitor aspirin
inhibited the venodilator effect of furosemide in our study. This observation serves as
a compelling validation of our results in chapter 3, and provides turther evidence that
prostaglandins are involved in the mechanism of this vascular action of furosemide
(MacKay et al, 1984). What is not clear, however, is precisely how inhibition of
prostaglandin synthesis inhibits venodilation. The most obvious explanation is that
aspirin inhibits the local production of prostaglandins, which provide the dilatory
stimulus to veins. Whether these are released directly in response to the action of
furosemide on the veins (Pickkers et al, 1997) or indirectly in response to the action
of angiotensin II on the venous endothelium (Gimbrone et al, 1975) is unknown. If
the latter is the mechanism, aspirin could block it at two sites. Aspirin may block
furosemide induced renal renin release, which is prostaglandin dependent (MacKay et
al, 1984; Goldiner et al, 1981; Tan et al, 1977) and hence, subsequent generation of
angiotensin II. Alternatively, aspirin could block the direct effect of angiotensin II on
veins, presumably mediated by cyclooxygenase.
4.4.2 Angiotensin II and venodilation
Involvement of angiotensin II in the process of venodilation (Johnston et al,
1983) would however seem unlikely in our patients. It has been previously reported
that beta-blocker therapy inhibits the acute renin release produced by intravenous
furosemide (Johnstone et al, 1985), and six of the eleven patients in our study were
taking a beta-blocker as part of their heart failure therapy. Furthermore, all eleven
patients in the furosemide study were taking an ACE inhibitor, yet they still displayed
venodilation in response to furosemide.
4.4.3 Direct effects of furosemide
A direct effect of furosemide in veins may be more likely and has previously
been described by Pickkers et al (1997). In their study furosemide was found to have
a direct dilatory effect on dorsal hand veins of healthy volunteers. The effect was
independent of nitric oxide, and the concentration of furosemide in the veins was far
less than the supra-therapeutic concentrations which are needed to inhibit the
chloride-dependent Na-K cotransport system (Ellory & Stewart, 1982). Instead, the
authors found that the effect of furosemide was blocked by cyclooxygenase inhibition
(with indomethacin) and was therefore deemed to be prostaglandin dependent. This
direct action of furosemide has not been reported by all authors (Harada et al, 1996).
Differences in the venoconstrictor used and the percentage of pre-constriction of the
veins before furosemide was administered could, however, account for this
discrepancy.
4.4.4 Effect of furosemide on endothelium
Further support for the hypothesis that furosemide stimulates prostaglandin
release through an action on the venous endothelium comes from an in vitro study by
Liguori et al (1999). These authors studied the effects of therapeutic concentrations
of furosemide on cultures of human umbilical vein endothelium. They reported that
secretion of prostacyclin, measured indirectly by 6-keto-prostaglandin Fia
production, increased within 5 minutes of exposure of the culture to furosemide.
Secretion was maximal at approximately 15 minutes and was maintained for 20 to 30
minutes. This time-scale for the release of prostacyclin fits well with our findings and
those of others that the venodilator effect of furosemide occurs within 15 to 20
minutes of drug administration in vivo.
4.4.5 Summary
We have demonstrated that venodilation occurs in patients with chronic heart
failure in the minutes following the administration of a 20mg intravenous dose of
furosemide. This is obviously potentially advantageous, even more so in the clinical
scenario of acute heart failure. Our observation that the venodilation could be
inhibited by both high and low dose aspirin further questions the use of aspirin in
patients with chronic heart failure, over and above the results of chapter 3.







Primary diagnosis IHD/IDC, n










































IHD = ischaemic heart disease; IDC = idiopathic dilated cardiomyopathy; NYHA















Figure 4.2 Effect of furosemide on venous capacitance according to aspirin
pre-treatment (aspirin 75mg versus placebo, p<.01; aspirin 300mg versus
placebo, p<.0001; aspirin 75mg versus aspirin 300mg, p=ns)
TIME (MINS)
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Figure 4.3 Effect of GTN on venous capacitance compared with effect of





























Effect of bradykinin and substance P in heart failure
5.1 introduction
As we have already observed, there is continuing controversy surrounding the
concomitant use of aspirin and angiotensin converting enzyme (ACE) inhibitors in
patients with congestive heart failure due to left ventricular systolic dysfunction
(Cleland et al, 1995). Whilst this hypothesis continues to await a definitive answer,
some progress can be made by studying some of the potential mechanisms for such an
interaction. As previously discussed, any interaction between aspirin and ACE
inhibitors must almost certainly involve prostaglandins, for while the effect of ACE
inhibitors may be quite complex, those of aspirin are almost certainly quite simple
(Vane et al, 1971). The most usual explanation for the interaction between aspirin
and ACE inhibitors therefore involves bradykinin. ACE inhibitors have been shown to
potentiate the effects of bradykinin by inhibition of its breakdown (Benjamin et al,
1989), and bradykinin has been shown to exert at least some of its effects via
prostaglandins, as described in chapter 3. It is therefore an inhibition by aspirin of
prostaglandin-mediated bradykinin-induced effects of ACE inhibitors which is
postulated to account for their negative interaction. We therefore sought to
determine whether or not aspirin actually has any effect on the response to bradykinin,
in patients with heart failure treated with an ACE inhibitor. We also took advantage
of the opportunity to examine the effect of aspirin on the response to another kinin,
substance P. Not usually invoked as a mediator of any sort of interaction between
aspirin and ACE inhibitors, substance P is a potent vasodilator, with evidence that it
may be potentiated by ACE inhibitors (Valdemarsson et al, 1991), and that it may




The study was conducted with the approval of the West Ethics Committee and
all patients gave written informed consent. Twelve patients with chronic heart failure
secondary to left ventricular systolic dysfunction confirmed by echocardiography were
studied (left ventricular ejection fraction <40%). All patients were clinically stable on
constant medication for 3 months, with no peripheral oedema or pulmonary
congestion, and no uncontrolled hypertension, hypercholesterolemia or diabetes
mellitus. All patients were treated with an ACE inhibitor (enalapril lOmg bd in the
majority). All medication apart from aspirin was constant throughout the study.
Patient characteristics are summarised in Table 5.1.
5.2.2 Treatment
Each patient was studied on two occasions, after 14 days of no aspirin at all,
and after 14 days of 150mg aspirin daily, having abstained from all other aspirin,
aspirin-containing medications or aspirin-like medications during that time. Patients
were not randomised, but studied in the order: Omg; 150mg. This dose is in the
middle of the range previously demonstrated by us to inhibit arterial vasodilation to
arachidonic acid (chapter 3) and venodilation to furosemide (chapter 4). Patients
took their usual medications including aspirin therapy as directed 6 hours before
attendance on the day of study. Patients abstained from alcohol, tobacco and caffeine
for 24 hours before each study and attended fasted for 6 hours. Bradykinin was
infused at 10, 30 and 100 pmol/min for 3 minutes at each dose and substance P was
infused at 1, 2 and 4 pmol/min for 3 minutes at each dose. Aspirin was then infused at
Img/min for 15 minutes. Bradykinin and substance P were then re-infused in the
same order as before (the order of infusion having been randomised). For the second
study, patients attended after taking oral aspirin for 14 days, and only the first part of
the study (bradykinin and substance P infusion) was repeated. Each patient therefore
had measurement of responses to bradykinin and substance P off all aspirin therapy,
after a single dose of intra-arterial aspirin only, and after 14 days of regular oral
aspirin only (in that order). The study design is summarised in Figure 5 .1.
5.2.3 Measurements
Forearm blood flow was measured by the technique of venous occlusion
plethysmography as described in chapter 2. Plethysmography recordings were made
at 10 minute intervals during saline infusion and at 3-5 minute intervals during drug
infusion. Blood pressure and pulse rate were manually recorded in the non-infused
arm at 5-10 minute intervals throughout each study.
5.2.4 Drugs
Bradykinin (purity 99.4% by HPLC) was obtained from Clinalfa AG
(Laufelfingen, Switzerland) and dissolved in normal saline. Substance P (purity
99.6% by HPLC) was obtained from Clinalfa AG and dissolved in normal saline.
Aspirin was obtained from Synthelabo France and dissolved in normal saline. All
drugs were always used within 2 hours of final preparation and destroyed thereafter.
5.2.5 Data analysis
All results are expressed as mean values with standard errors. All results were
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Local infusion of bradykinin, substance P and aspirin caused no adverse or
systemic effects, and patients did not report any discomfort. Pulse rate, blood
pressure, and forearm blood flow in the non-infused forearm did not change
significantly during either of the studies, and there were no significant differences in
baseline pulse rate, blood pressure or baseline forearm blood flow between either of
the studies.
5.3.2 Effect of bradykinin
Bradykinin caused marked vasodilation, which was rapid in onset (~1 minute)
and almost as rapid in offset (~5 minutes). There was obvious flushing of the whole
forearm at the highest dose of bradykinin in the majority of cases, although no patient
complained of this spontaneously. There was a clear dose-response relationship, with
peak vasodilation at the highest dose of 100 pmol/min, and no sign of the
development of significant tachyphylaxis (Figure 5 .2).
5.3.3 Effect of substance P
Substance P caused vasodilation, which was even more rapid in onset and
offset. The magnitude of vasodilation to substance P was rather less than that to
bradykinin, at the much lower doses used. Vasodilation to 4 pmol/min of substance P
was rather more than the vasodilation to 10 pmol/min of bradykinin. There was again
a clear dose-response relationship, with peak vasodilation at the highest dose of 4
pmol/min, and no sign of the development of significant tachyphylaxis (Figure 5.3).
5.3.4 Effect of intra-arterial aspirin
Intra-arterial aspirin had no significant effect on forearm blood flow on its own
(Figure 5.4). There was a trend towards vasoconstriction which was significant at 15
minutes but not at 10 and 5 minutes, and not over the whole 15 minutes.
5.3.5 Effect of intra-arterial aspirin on bradykinin/substance P
Intra-arterial aspirin had no significant effect on the vasodilator response to
either intra-arterial bradykinin (Figure 5.2) or substance P (Figure 5.3).
5.3.6 Effect of oral aspirin on bradykinin/substance P
Aspirin 150mg a day for 14 days had no significant effect on the vasodilator
response to either intra-arterial bradykinin (Figure 5.2) or substance P (Figure 5.3).
Although there appeared to be a slight reduction in the response to bradykinin,
particularly at the highest dose of bradykinin, this was not significant and was in any
case modest in proportion compared to the magnitude of the vasodilator response.
5.4 Discussion
In this study in the forearm of patients with heart failure, we have shown that
exogenous bradykinin and substance P cause vasodilation, that intra-arterial aspirin
has no obvious effect on its own, that intra-arterial aspirin has no effect on the
response to bradykinin or substance P, and that 14 days oral aspirin 150mg od has no
effect on the response to bradykinin or substance P. All these findings are novel,
interesting in their own right, and have wider implications.
5.4,1 Effect of bradykinin in heart failure
This is the first study we are aware of that has examined the effects of
exogenous bradykinin in human patients with heart failure. Bradykinin has been
studied in healthy volunteers (Fox et a/, 1961) and in patients with endothelial
dysfunction (Panza et al, 1995), but not previously in patients with heart failure,
despite the importance of ACE inhibitors and the potential importance of bradykinin
potentiation in heart failure. Our findings confirm that bradykinin is a potent
vasodilator in patients with heart failure treated with an ACE inhibitor, as it is in
subjects without heart failure. Furthermore, they suggest the hypothesis that this may
be one endothelium-dependent response, which is not impaired in heart failure, at least
not markedly. Unfortunately, we did not have the opportunity to study healthy
controls, but our recordings really are remarkably similar to those seen previously in
healthy volunteers also treated with an ACE inhibitor (Figure 5.5), albeit acutely
rather than chronically (Cockcroft et al, 1993). Obviously it is possible that there is a
difference between chronic and acute treatment which cancels out a difference
between heart failure and normal, but interestingly it has recently been reported that
responses to exogenous bradykinin are indeed unimpaired in heart failure, albeit an
animal model (Su et al, 1998). This is perhaps all the more surprising given that heart
failure has also been reported to increase plasma levels ofbradykinin, also in an animal
model (Cheng et al, 1998).
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5.4.2 Effect of substance P in heart failure
Unlike bradykinin, substance P has been studied in heart failure, as well as
other models of endothelial dysfunction, although the results of this have been
somewhat inconsistent. The only other study to look at the effects of substance P in
the forearm of patients with heart failure found that vasodilation was unimpaired,
allowing for the lower basal blood flow in patients compared with controls (Hirooka
et al, 1992). Of course, this rather begs the question of how to adjust responses for
lower basal blood flow in the first place. Absolute changes in blood flow are
obviously fairly meaningless, but there is no guarantee that relative changes are any
more meaningful. Under these circumstances, it is perhaps no surprise that a different
study examined endothelium-dependent responses in the lower limb, and found that
the response to substance P was reduced in patients compared with controls, albeit to
a lesser extent than the response to acetylcholine (Lindsay et al, 1996). Other studies
have been in vitro (Berkenboom et al, 1987) or in animal models of heart failure
(Rubinstein et al, 1994). Yet other studies have found that the response to substance
P is reduced in patients with endothelial dysfunction due to hypertension (Panza et al,
1994) and that the response to substance P is not reduced in patients with endothelial
dysfunction due to atherosclerosis (Husain et al, 1998). We found obvious
vasodilation to substance P in patients with heart failure treated with an ACE
inhibitor. There are unfortunately no previous studies of the effect of substance P in
patients treated with an ACE inhibitor, and we did not have the opportunity to study
the effect of substance P in healthy controls. Although comparison with the effects of
bradykinin suggests this vasodilation is quite modest, the molar doses of substance P
were multiple orders of magnitude smaller. The role of substance P as a potent
vasodilator, even in heart failure, at least when treated with an ACE inhibitor, is
hereby reiterated.
5.4.3 Effect of intra-arterial aspirin
At first site, our findings with intra-arterial aspirin would appear to be
markedly at odds with the one previous study to report directly on the effects of intra¬
arterial aspirin. Duffy et al (1998) found a significant reduction in forearm blood flow
with intra-arterial aspirin infusion. However, the two sets of findings are not as
incompatible as they might at first sight appear to be. Comparing the time course of
our findings at 1 mg/min with the previous findings at 3 mg/min reveals only one time
point (10 minutes), when our findings were significantly different (Figure 5.6).
Comparing our findings with the dose-response curve of the previous study reveals
that our findings at 1 mg/min were compatible with the previous findings at the same
dose (Figure 5.7). We deliberately chose to avoid higher doses or a more prolonged
infusion because of the risk that that would lead to supra-pharmacoactive
concentrations in the forearm, or even pharmacoactive concentrations systemically.
Of course the slight difference between our findings and the previous findings could
relate to a difference between health and disease or a difference between treatment
and no treatment.
5.4.4 Interaction of bradykinin and aspirin
Our findings show no significant effect of aspirin, whether intra-arterial or
oral, on the vasodilator response to bradykinin in patients with heart failure treated
with an ACE inhibitor. The effects of bradykinin are frequently said to be aspirin-
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sensitive and this sensitivity is frequently invoked as a potential mechanism for the
reported negative interaction between aspirin and ACE inhibitors. Despite this, the
evidence that aspirin actually affects the vascular effects of bradykinin is patchy (see
also discussion in chapter 3). There is no doubt that aspirin blocks the algesic effects
of bradykinin (Cofiffnan et al, 1966), indeed this is probably central to the analgesic
activity of aspirin and aspirin-like drugs (Moncada et al, 1975). There are also well-
validated instances of inhibition of smooth muscle motor responses to bradykinin by
aspirin (Ono el al, 1977; Walker el al, 1979), and yet the effect of aspirin on
vasomotor responses to bradykinin is much more variable. There seems no doubt that
aspirin blocks the release of vasoactive prostanoids by bradykinin (Heavey et al, 1985;
flitter et al, 1989; Clarke el al, 1991; Keimowitz et al, 1993). Despite this there are at
least four reports (Benjamin et al, 1989; Heavey et al, 1985; Ritter et al, 1989; Bhagat
et al, 1995) that aspirin has no effect on the vasodilator response to bradykinin. Most
of the reports that aspirin does block the vasomotor effects of bradykinin have been in
vitro (Toda et al, 1977; Fasciolo et al, 1990) or in animals (Fasciolo et al, 1990;
Turker et al, 1982; Copeland et al, 1995). Our findings add to the evidence that
aspirin does not block the vasodilator effect of bradykinin, and extend that finding to
patients with heart failure treated with an ACE inhibitor, a group in whom this is of
considerable interest.
5.4.5 Interaction of substance P and aspirin
Our findings show no significant effect of aspirin, whether intra-arterial or
oral, on the vasodilator response to substance P in patients with heart failure treated
with an ACE inhibitor. Potentiation of substance P by inhibition of its breakdown is
frequently invoked as a possible cause of side effects such as cough in patients treated
with an ACE inhibitor (Emanueli et al, 1998; Yeo el al, 1995). This is despite the fact
that the most direct examination of the interaction between substance P and an ACE
inhibitor found absolutely no evidence of any effect whatsoever (Benjamin el al,
1990). Any evidence that the effects of substance P were mediated by prostaglandins
and blocked by aspirin might still be highly pertinent to the reported negative
interaction between aspirin and ACE inhibitors. As with bradykinin. there is little
doubt that aspirin blocks the algesic effects of substance P (Elunskaar el al, 1985),
and again, this is perhaps somewhat central to the analgesic effect of aspirin. As with
bradykinin, the evidence that aspirin blocks the vasodilator effects of substance P is
patchy, venodilation apparently being blocked (Strobel et al, 1996), and arterial
vasodilation (at least in patients with atherosclerosis) apparently not (Husain et al,
1998). Our findings add to the evidence that aspirin does not block the vasodilator
effect of substance P, at least in patients with heart failure treated with an ACE
inhibitor. This is a group in whom this is of considerable interest, given that substance
P levels are elevated in heart failure (Edvinsson et al, 1990), and further elevated by
treatment with ACE inhibitors (Valdemarsson et al, 1991). We can only assume that
the mechanism for this elevation, if it is real, is an indirect rather than a direct one.
5.4.6 Summary
We have shown that exogenous bradykinin and substance P cause vasodilation
in patients with heart failure, that there is no evidence of any effect of intra-arterial
aspirin on its own, and that there is no evidence of any effect of aspirin, intra-arterial
or oral, on the responses to bradykinin and substance P. Given the fairly small
numbers involved, we cannot rule out a type II error (i.e., a false negative), but the
strength of the response to bradykinin and substance P and the lack of any obvious
response to aspirin rules out anything but quite a subtle influence of aspirin on these
mediators. Demonstration of these responses is completely novel in patients with
heart failure, and is only partly consistent with previous work in vitro, in animals and
in healthy volunteers. Whilst these findings leave open the issue of whether
bradykinin or substance P contributes to the non-angiotensinergic effects of ACE
inhibitors, they do suggest that neither bradykinin nor substance P can be invoked as a
mechanism to explain the reported negative interaction between aspirin and ACE
inhibitors, and proponents of this hypothesis will need to look to other mediators to
incriminate, perhaps, for example, angiotensin-^ 1-7) (Ferrario et a!, 1991).
91
Table 5.1 Patient Characteristics
Patient Characteristic
Sex, n 10 M/2 F
Age, y (mean+SD) 63±6
Primary diagnosis IHD/IDC, n 10/2
NYHA functional class II/III/IV, n 7/4/1
LVEF, % (mean±SD) 20±7
Current smoker, n 4
On Diuretic, n 12
ACE inhibitor, n 12
Enalapril 1 Omg bd, n 9
Aspirin, n 9
Statin, n 6
Beta blocker, n 3
Digoxin, n 3
Nitrate, n 1
IHD = ischaemic heart disease; IDC = idiopathic dilated cardiomyopathy; NYHA =







Figure 5.2 Effect of bradykinin on forearm blood flow before and after intra¬
arterial and oral aspirin (BK = no aspirin; BK+A(IA) = after intra-arterial
aspirin; BK+A(0) = after 14 days oral aspirin: p=ns for BK versus BK+A(IA),
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Figure 5.3 Effect of substance P on forearm blood flow before and after
intra-arterial and oral aspirin (SP = no aspirin; SP+A(IA) = after intra-arterial
aspirin; SP+A(0) = after 14 days oral aspirin: p=ns for SP versus SP+A(IA),
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Figure 5.5 Comparison between our results with bradykinin ( in heart failure
patients established on ACE inhibitor) & those of Coekcroft et al (in healthy
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Figure 5.6 Comparison between the time course of our results with aspirin (1
mg/min) and those of Duffy et al (3 mg/min)
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Figure 5.7 Comparison between dose-response of our results with aspirin (1

























Effect of bradykinin antagonism in heart failure
6.1 Introduction
It is has long been known that angiotensin converting enzyme (ACE) is
identical to kininase II, the most important pathway for degradation of bradykinin
(Yang et al, 1970). Indeed, when parenterally active ACE inhibitors first became
available they were known as bradykinin-potentiating peptides (Gavras et al, 1974).
Parenterally active angiotensin II type I receptor (ATI) antagonists became available
around the same time (Solomon et al, 1974). Shortly afterwards, orally active ACE
inhibitors became available (Gavras et al, 1978), and the focus of interest switched to
their effects alone, as it was a long time before orally active AT 1 antagonists became
available (Chiu et al, 1990). Now that orally active ACE inhibitors and ATI
antagonists are both readily available, the focus of interest is switching from their
similarities towards their differences. The most obvious difference remains that ACE
inhibitors are bradykinin-potentiating whereas ATI antagonists are not, at least, not
directly, as far as we know. Despite this, it is not known to what extent endogenous
bradykinin-potentiation actually contributes to the beneficial effects or side effects of
ACE inhibitors in patients with heart failure. Whilst it is indisputable that ATI
antagonists have a better side effect profile than ACE inhibitors (Pitt et al, 1997), it is
not known at all whether they share the same beneficial effects overall. As work
continues to develop the use of ATI antagonists in heart failure, it is important that
their differences from ACE inhibitors are scrutinised, and the role of bradykinin in the
effects of either or both better defined. Recently, a potent, selective and long-acting
bradykinin type 2 receptor (B2) antagonist, Eloe-140 (for which the name icatibant
has also been proposed), has become available (Hock et al, 1991; Wirth et al, 1991).
This gives us an exciting opportunity to scrutinise the effects of bradykinin in this
area, as most of the clinically relevant effects of bradykinin are mediated through the
B2 receptor (Regoli el al, 1980, 1990). In this study, we examined the effects of
bradykinin, Hoe-140, and their combination in patients with heart failure randomised
to double-blind cross-over treatment with an ACE inhibitor and an ATI antagonist.
6.2 Methods
6.2.1 Patients
The study was conducted with the approval of the West Ethics Committee and
all patients gave written informed consent. Twelve patients with chronic heart failure
secondary to left ventricular systolic dysfunction confirmed by echocardiography were
studied (left ventricular ejection fraction <40%). All patients were clinically stable on
constant medication for 3 months, with no peripheral oedema or pulmonary
congestion, and no uncontrolled hypertension, hypercholesterolaemia or diabetes
mellitus. All patients were treated with an ACE inhibitor at baseline (enalapril lOmg
bd in the majority). All medication apart from ACE inhibitor/ATI antagonist and
aspirin was constant throughout the study. Patient characteristics are summarised in
Table 6.1. Eight of the twelve patients also took part in a pilot and dose-ranging
study whilst taking their usual ACE inhibitor, in order to confirm the safety of
intrabrachial Hoe-140 and establish an appropriate dose for demonstration of its
arterial vasomotor effects (if any).
6.2.2 Randomisation
Patients were randomised to double-blind cross-over treatment with enalapril
lOmg bd for 5 weeks followed immediately by losartan 25mg bd for 5 weeks, or vice
versa. The doses of enalapril and losartan were both chosen on the basis of the best-
available evidence, randomised controlled trials with proper clinical endpoints. The
dose of enalapril was taken from the SOLVD trials (1991; 1992), and the dose of
losartan was taken from the ELITE study (Pitt et al, 1997), split into two doses for
ease of blinding. Although we cannot be certain that these doses are equivalent, it is
so difficult to settle on equivalent doses of different ACE inhibitors, let alone ACE
inhibitors and other drugs, that randomised controlled trials with proper clinical
endpoints are all we have to go on. At the end of each 5 week study period patients
attended for venous occlusion plethysmography, having abstained from all aspirin
therapy for 14 days. Patients took their usual medications except for aspirin and
including enalapril/losartan 6 hours before attendance on the day of study. Patients
abstained from alcohol, tobacco and caffeine for 24 hours before each study and
attended fasted for 6 hours.
6,2.3 Treatment
In the first few pilot studies, Hoe-140 was infused at 90 pg/min for 15
minutes, as alluded to in the study by Groves et al (1995). When further dose-ranging
studies were required, the doses arbitrarily chosen were 45, 23, 12 and 6 pg/min each
for 15minutes. The dose finally settled on was 7 pg/min for 30 minutes (the total
dose was therefore 21 Opg).
In the main study, bradykinin was infused at 10, 30 and lOOpmol/min for 3
minutes at each dose, Hoe-140 was infused as above, and then bradykinin was re-
infused as before. After the first study patients immediately crossed-over to the other
double-blind treatment period, at the end of which they returned for the second study
which was conducted in exactly the same way. The study protocol is summarised in
Figure 6.1.
6.2.4 Measurements
Forearm blood flow was measured by the technique of venous occlusion
plethysmography as described in chapter 2. Plethysmography recordings were made
for a period of 2% minutes at 10 minute intervals during saline inftision and at 3-5
minute intervals during drug infusion. Blood pressure and pulse rate were manually
recorded in the non-infused arm at 5-10 minute intervals throughout the study.
6.2.5 Drugs
Bradykinin (purity 99.4% by FfPLC) was obtained from Clinalfa AG
(Laufelfingen, Switzerland) and dissolved in normal saline. Hoe-140 (purity 99.9% by
HPLC) was obtained from Peptides International (Louisville, Kentucky, USA) and
dissolved in normal saline. Both drugs were always used within 2 hours of final
preparation and destroyed thereafter.
6.2.6 Data analysis
All results are expressed as mean values with standard errors. All results were
compared using two-tailed paired t tests. Differences were considered significant at a




Local infusion of bradykinin and Hoe-140 caused no adverse or systemic
effects, and patients did not report any discomfort. Pulse rate (Figure 6.2), blood
pressure (Figure 6.3), and forearm blood flow in the non-infused forearm did not
change significantly during either of the studies. There were no significant differences
in baseline pulse rate (Figure 6.2), blood pressure (Figure 6.3) or baseline forearm
blood flow between either of the studies (although there was a trend towards a lower
blood pressure and a higher baseline forearm blood flow in the enalapril study
compared with the losartan study).
6.3.2 Pilot and dose-ranging studies
The initial four studies were closely modelled after the pilot study alluded to
by Groves et al (1995), as this was the only mention of any forearm studies with Hoe-
140 in the literature at the time. Hoe-140 was therefore infused at 90 pg/min, albeit
for 20 minutes rather than the 15 minutes of the previous studies. There was no
obvious effect of this dose on its own, but it did result in profound blockade of the
vasodilator effects of exogenous bradykinin. This was in marked contrast to the result
of Groves et al, who reported that the same dose caused a 24% reduction in forearm
blood flow (this was a pilot study for the main study of the effects of Hoe-140 on
coronary blood flow). The only way we could explain this (apart from Hoe-140
having no effect) was to postulate that perhaps Hoe-140 was acting as a partial
agonist, i.e., a mixed antagonist and agonist. We therefore set about finding the
minimum dose which provided effective blockade of the effects of exogenous
bradykinin (arbitrarily considered to be 50% inhibition of the effects of the highest
dose of bradykinin used). The doses tried were 45, 23, 12 and 6 (ig/min each for 15
minutes, and whilst there were no obvious effects of any of these on their own, all
provided varying degrees of blockade of exogenous bradykinin. We therefore settled
on a 30 minute infusion of 7 (.ig/min as a compromise.
6.3.3 Effect of bradykinin
Bradykinin caused marked vasodilation which was rapid in onset (~ 1 minute)
and almost as rapid in offset (~5 minutes). There was obvious flushing of the whole
forearm at the highest dose of bradykinin in the majority of cases, although no patient
complained of this spontaneously. There was a clear dose-response relationship, with
peak vasodilation at the highest dose of 100 pmol/min, and no sign of the
development of significant tachyphylaxis (Figure 6.4). There was a very obvious
effect of pre-treatment, with more vasodilation to bradykinin in the enalapril study
than in the losartan study (163+33%; 248+62%; 357+67% versus 36+10%;
103+19%; 230+46%: p=0.0002). Indeed, in the middle of the dose-response range
demonstrated, vasodilation to 100 pmol/min of bradykinin in the losartan study was
not significantly different from that to 30 pmol/min or 10 pmol/min in the enalapril
study (230+46% versus 248+62%, p=ns; 230+46% versus 163+33%, p=ns).
6.3.4 Effect ofHoe-140
Hoe-140 had no effect on its own, either in the enalapril study or in the
losartan study. Although there appeared to be slight vasoconstriction to Hoe-140 in
the enalapril study, this was not significantly different from the response in the
losartan study, and only slightly different from baseline. Even if this were taken to
signify vasoconstriction, which our study is underpowered to detect, it is extremely
mild in degree (vasoconstriction at 30 minutes, 4+2%, Figure 6.5). Furthermore, a
dose of Hoe-140 almost seven times higher, given to four out of the twelve patients
whilst taking their usual ACE inhibitor, produced a similar lack of response (an
apparent vasodilation of 8+2%).
6.3.5 Effect of bradykinin after Hoe-140
Bradykinin again caused vasodilation, rather less than before, although the
dose-response relationship was clearly preserved (Figure 6.4). This was certainly not
due to the development of tachyphylaxis. At the lower doses of bradykinin,
vasodilation was almost completely abolished. The effect of pre-treatment with
enalapril or losartan was again clearly preserved. In the middle of the response-range
demonstrated, vasodilation to bradykinin following Hoe-140 in the enalapril study was
not significantly different from that preceding Hoe-140 in the losartan study (peak
vasodilation 192+46% versus 230+46%, p=ns). Furthermore, vasodilation to 100
pmol/min of bradykinin following Hoe-140 was not significantly different from that to
30 pmol/min or 10 pmol/min preceding Hoe-140 in the enalapril study (192+26%
versus 248+62%, p=ns; 192+26% versus 163+33%, p=ns). Vasodilation to
bradykinin following Floe-140 in the losartan study was very modest indeed compared
to the other responses in this study (peak vasodilation 66+13%).
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6.4 Discussion
In this study we have shown that exogenous bradykinin causes vasodilation in
the forearm of patients with heart failure, that this response is enhanced by pre-
treatment with an ACE inhibitor as compared with an ATI antagonist, and that
endogenous bradykinin antagonism with Hoe-140 has no significant effects on its
own, irrespective of pre-treatment with an ACE inhibitor or an AT 1 antagonist, even
though it provides effective antagonism of exogenous bradykinin. All these findings
are novel, interesting in their own right, and have wider implications.
6.4.1 Effect of bradykinin in heart failure
Our findings with bradykinin in this study replicate and validate our findings
with bradykinin in chapter 5. The findings from this study confirm that bradykinin is a
potent vasodilator in patients with heart failure, as it is in subjects without heart
failure. As we have already observed it has recently been reported that responses to
bradykinin are unimpaired in an animal model of heart failure (Su el al, 1998), but at
the time ofwriting ours are the only studies of the effect of bradykinin in humans with
heart failure in the entire literature (Davie et al, 1999).
6.4.2 Bradykinin and ACE inhibitors and ATI antagonists
It is known that ACE inhibition increases forearm blood flow in response to
bradykinin (Benjamin et al, 1989). Indeed, one previous study has compared the
effect of enalapril with that of losartan on the forearm blood flow response to
bradykinin (Cockcroft et al, 1993). Our study usefully adds to what is known about
the role of bradykinin in the effects of ACE inhibitors and ATI antagonists. Rather
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than healthy volunteers, our study used patients with heart failure, the very patients in
whom the effects of ACE inhibitors and ATI antagonists, and the role of bradykinin,
are of most concern. Also, we examined the effects of chronic (5 weeks) oral
treatment with enalapril/losartan, rather than the acute response examined after intra¬
arterial enalaprilat (Benjamin et al, 1989), or a single oral dose of enalapril/losartan
(Cockcroft et al, 1993). It is well known that the acute effects of ACE inhibitors may
differ quite markedly from their chronic effects (Sharpe et al, 1980; Juillerat et al,
1990; Drexler et al, 1989), which are obviously of more clinical interest. It is not
known to what extent the chronic effects of ATI antagonists might differ from their
acute effects. Despite these considerations, our findings, in patients with heart failure
studied after chronic treatment, really are remarkably similar to those in healthy
volunteers studied after acute treatment (Figure 6.6) (Cockcroft et al, 1993). This is
perhaps even more surprising given that ACE inhibitors have been reported to cause
down-regulation of bradykinin receptors (Yasujima et al, 1981). Obviously it is
possible that some sort of difference between patients and volunteers is cancelled out
by chronic versus acute treatment, or vice versa. In any case, our findings confirm
what has been found previously, and extend those findings to a more clinically
relevant setting.
6.4.3 Effect of bradykinin antagonism
It is surprising that we found no significant effect of antagonism of
endogenous bradykinin with Hoe-140. It has been reported that intra-arterial Hoe-
140 on its own has no significant effect on resting blood flow, although it reduces the
increase in radial artery diameter (but not the increase in blood flow) following wrist
arterial occlusion (Hornig et al, 1997). The only other published report of the effects
ofHoe-140 in the forearm of humans showed no haemodynamic effect of intravenous
administration (Cockcroft el al, 1994). These previous studies were in healthy
volunteers, rather than patients with heart failure on any sort of treatment. Even in
patients with heart failure, even when treated with an ACE inhibitor, we found no
acute haemodynamic effect of antagonism of endogenous bradykinin with Hoe-140.
This suggests that there is a complete discrepancy between the very obvious
potentiation of exogenous bradykinin by ACE inhibitors and the lack of evidence of
potentiation of endogenous bradykinin. These findings are of course consistent with
the evidence that ACE inhibitors do not actually increase plasma levels of bradykinin
(Johnston et al, 1979; Johnston et al, 1981).
6.4.4 Interaction of bradykinin antagonism and ACE inhibition
Our findings would initially appear to be at odds with a recent report that
some (but not all) of the acute haemodynamic effects of oral captopril are attenuated
by co-administration by of intravenous Hoe-140 (Gainer et al, 1998). This implies
that potentiation of endogenous bradykinin does contribute to the haemodynamic
effects of ACE inhibition. Apart from the superficial differences between this study
and our own (hypertensives versus heart failure patients, captopril versus enalapril,
intravenous versus intra-arterial Hoe-140), the most important difference is that of
timing. The doses of Hoe-140 were certainly of the same order of magnitude. Whilst
we administered 210pg over a period of 30 minutes in the forearm (average mass
~ 1 kg), Gainer et al administered a bolus of 100 pg/kg. Whereas Gainer et al
examined the effect of Hoe-140 on the effects of a single dose of captopril, we
examined the effect of Hoe-140 in patients treated with enalapril (or losartan) for 5
weeks. As we have already observed, the chronic effects of ACE inhibitors may be
quite different from their acute effects (Sharpe et al, 1980; Juillerat et al, 1990;
Drexler et al, 1989). Gainer et al made a similar observation, and called for a study
of the role of bradykinin during long term ACE inhibition. Our findings answer that
call.
6.4.5. Local versus systemic effects
One further difference between Gainer et aPs study and our own is that
between a systemic haemodynamic study and a local haemodynamic study. Obviously
each has its strengths and weaknesses and probably both are required for full
characterisation of any mechanism. The discrepancy might be construed as evidence
that forearm vascular responses are not relevant to the effect of ACE inhibitors.
Apart from the fact that enalaprilat has been shown to be directly vasodilating in the
forearm (Bank et al, 1991), as have angiotensin receptor blockers (Newby et al,
1997), it is well-established that ACE inhibitors do increase forearm blood flow
chronically if not necessarily acutely (Faxon et al, 1982). Furthermore, even when
intrabrachial enalaprilat has failed to have any effect on its own, it has clearly reduced
responsiveness to intrabrachial angiotensin I and increased responsiveness to
intrabrachial bradykinin (Benjamin et al, 1989), just as enalapril has affected the latter
in this study.
6.4.6 Effectiveness of bradykinin antagonism
The final part of our study confirmed that intra-arterial Hoe-140 antagonised
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the effects of exogenous bradykinin, despite the lack of any effect of Hoe-140 on its
own. It has previously been shown that intravenous Hoe-140 antagonises the effects
of intra-arterial bradykinin (Cockcroft et al, 1994), and it has previously been shown
that intra-arterial Hoe-140 blocks the effect of intra-arterial quinaprilat on flow-
dependent dilation in the form of reactive hyperaemia (Hornig et al, 1997). This is the
first study of the interaction of intra-arterial Hoe-140 and intra-arterial bradykinin, and
the interaction of that interaction with chronic oral (5 weeks) treatment with ACE
inhibitor/ATI antagonist, in patients with or without heart failure. The dose of Hoe-
140 used was lower than previous studies (Hornig et al, 1997), because we
deliberately sought to use the lowest dose capable of providing effective antagonism
of exogenous bradykinin. A higher dose of Hoe-140 had a similar lack of obvious
effect on its own. It is clear that the lower dose did not provide complete antagonism
of exogenous bradykinin, although it did do so at the lower doses of bradykinin used.
It is important to note that the doses of bradykinin used were massively supra-
physiological, perhaps by as much as three orders of magnitude (Hornig et al, 1997),
and the level of blockade achieved must therefore be regarded as similarly profound.
The possibility that the reduction observed could be ascribed to tachyphylaxis can be
discounted, as our own observations (chapters 4 & 6) and others' (Cheng et al, 1998),
have shown that although tachyphylaxis to bradykinin occurs, it is much more modest.
6.4.7 Interaction between aspirin and ACE inhibitors
Our findings are also relevant to the ongoing controversy surrounding the
potential negative interaction between ACE inhibitors and aspirin (Hall et al, 1992).
If such an interaction exists it is usually postulated that it is because of the effect of
aspirin on prostanoid-mediated effects of bradykinin (Cleland et al, 1995). It now
seems possible that exogenous bradykinin potentiation may turn out to be an
epiphenomenon of ACE inhibition, not necessarily relevant to the effects of ACE
inhibition on endogenous bradykinin activity. In this case, there will then be no
obvious substrate on which aspirin can exert its effects, and the proponents of this
theory will have to look elsewhere for evidence to sustain their hypothesis.
6.4.8. Summary
We have shown that exogenous bradykinin does cause vasodilation in patients
with heart failure and that this response is markedly enhanced by pre-treatment with
an ACE inhibitor as compared with an ATI antagonist. This is despite the fact that
there is no evidence of an effect of endogenous bradykinin antagonism with Hoe-140,
irrespective of pre-treatment with an ACE inhibitor or an ATI antagonist.
Simultaneous demonstration of this discrepancy is completely novel and has never
before been achieved in patients with heart failure, although it is largely consistent
with previous work in vitro, in animals and in healthy volunteers. This leaves intact
the hypothesis that AT 1 antagonists should not share all of the side effects of ACE
inhibitors. It calls into question, however, whether or not they will share all their
beneficial effects, and shows how little is known about how both act.
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Table 6.1 Patient Characteristics
Patient Characteristic
Sex, n 11 M/l F
Age, y (mean+SD) 69+8
Primary diagnosis IHD/IDC, n 9/3
NYHA functional class H/HI, n 6/6
LVEF, % (mean±SD) 23+9
Current smoker, n 3
On Diuretic, n 12
ACE inhibitor, n 12
Enalapril 1 Omg bd, n 10
Aspirin, n 8




Calcium antagonist, n 2
Amiodarone, n 1
Oral hypoglycaemic 1
Body mass index, kg/m2 (mean±SD) 26+5
Cholesterol, mmol/1 (mean+SD) 5.4±0.8
Trigycerides, mmol/1 (mean±SD) 2.4+1.1
IHD = ischaemic heart disease; IDC = idiopathic dilated cardiomyopathy; NYHA =












Figure 6.2 Heart rate during Hoe-140 infusion in 12 patients according to


















Figure 6.3 Mean blood pressure during Hoe-140 infusion in 12 patients
























Figure 6.4 Effect of bradykinin on forearm blood flow before and after Hoe-
140 (E = enalapril before Hoe-140; L = losartan before Hoe-140; E+H =
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Figure 6.6 Comparison between our results with bradykinin in patients with
heart failure and those of Cockcroft et al in healthy volunteers (E (Davie) = after
5 weeks of enalapril 10mg bd; E (Cockcroft) = after single dose of enalapril
lOmg; L (Davie) = after 5 weeks of losartan 25ing bd; L (Cockcroft) = after
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Effect of angiotensin-(l-7) in heart failure
7.1 Introduction
Angiotensin^ 1-7) was originally regarded as a biologically inactive
degradation product of the renin-angiotensin-system (Nussberger et al, 1983; Tonnaer
et al, 1983). An early study reported pressor effects in humans in vivo, but at such
large doses that it could only be regarded as confirmation of biological inactivity
(0.028% of the activity of angiotensin II) (Kono et al, 1986). It has since emerged
that angiotensin^ 1-7) is biologically active in the central nervous system
(Campagnole-Santos et al, 1989), and indeed in the circulation (Osei et al, 1993). It
has also emerged that angiotensin^ 1-7) levels are not reduced by ACE inhibition
(Welches et al, 1991), but may be increased, which implies that it is derived direct
from angiotensin 1 (Campbell et al, 1991), and that the effect of angiotensin^ 1-7) is
potentiated by ACE inhibition (Porsti et al, 1994), which implies that it is inactivated
by ACE (Chappell et al, 1998). It is therefore hypothesised that angiotensin^ 1-7)
may contribute towards the "non-angiotensin-Il-ergic" effects of ACE inhibitors (Iyer
et al, 1998), and even that this may be one way in which inhibitors of prostaglandin
synthesis could interfere (Benter et al, 1993) with the action of ACE inhibitors (Hall
et al, 1992). The situation is further complicated by the fact that angiotensin^ 1-7)
has been shown to interact closely with the effects of bradykinin. It is clear that it
potentiates the effect of bradykinin (Paula et al, 1995), and even that its effects may
be mediated by bradykinin (Abbas et al, 1997). Given that the effects of bradykinin
are also potentiated by ACE inhibitors (Benjamin et al, 1989), this reiterates the
potential importance of angiotensin^ 1-7) (and bradykinin) in the effects of ACE
inhibitors. It is hardly surprising that it has even been suggested that angiotensin^ 1-
7) may be acting as an ACE inhibitor itself (Li et al, 1997; Deddish et al, 1998; Roks
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etal, 1999)
With a single exception (Kono el al, 1986), these studies were conducted in
animals not humans, or were conducted in vitro rather than in vivo. Furthermore,
despite the potential importance of angiotensin^ 1-7) in the effects of ACE inhibitors,
there has been no examination of its effects in heart failure, a syndrome in which the
renin-angiotensin-system is of enormous importance and ACE inhibitors are
extraordinarily clinically useful. We therefore sought to discover the effects of
angiotensin^ 1-7) in patients with heart failure treated with an ACE inhibitor, and any
interaction with the effects of bradykinin.
7.2 Methods
7.2.1 Patients
The study was conducted with the approval of the West Ethics Committee and
all patients gave written informed consent. Eight patients with chronic heart failure
secondary to left ventricular systolic dysfunction confirmed by echocardiography were
studied (left ventricular ejection fraction <40%). All patients were clinically stable on
constant medication for 3 months, with no peripheral oedema or pulmonary
congestion, and no uncontrolled hypertension, hypercholesterolaemia or diabetes
mellitus. All patients were treated with an ACE inhibitor (5 patients enalapril lOmg
bd, 1 patient lisinopril lOmg od, 1 patient captopril 25mg tds, 1 patient perindopril
4mg bd). All medication apart from aspirin was constant throughout the study.
Patient characteristics are summarised in Table 7.1.
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7.2.2 Treatment
Patients were studied after 14 days abstinence from aspirin. They took their
usual medications apart from aspirin 6 hours before attendance on the day of study.
Patients abstained from alcohol, tobacco and caffeine for 24 hours before each study
and attended fasted for 6 hours. Bradykinin was infused at 3, 10 and 30 pmol/min for
3 minutes at each dose. Angiotensin-^ 1-7) was then infused at 5, 50, 500, 5000 and
50000 pmol/min for 6 minutes at each dose. These doses were almost completely
arbitrary, as there are no previous reports of forearm studies with angiotensin-(l-7) in
the literature. The doses were chosen to give as wide a dose-range from a single vial
as possible, and to include potentially systemically active doses as well as potentially
locally active doses. Finally, bradykinin was re-infused as before whilst a co-infusion
of angiotensin^ 1 -7) at 50000 pmol/min continued.
7.2.3 Measurements
Forearm blood flow was measured by the technique of venous occlusion
plethysmography as described in chapter 2. Plethysmography recordings were made
at 10 minute intervals during saline infusion and at 3-5 minute intervals during drug
infusion. Blood pressure and pulse rate were manually recorded in the non-infused
arm at 5-10 minute intervals throughout each study.
7.2.4 Drugs
Bradykinin (purity 99.4% by FfPLC) was obtained from Clinalfa AG
(Laufelfmgen, Switzerland) and dissolved in normal saline. Angiotensin^ 1 -7) (purity
99.9% by HPLC) was obtained from Clinalfa AG and dissolved in normal saline.
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Both drugs were always used within 2 hours of final preparation and destroyed
thereafter.
7.2.5 Data analysis
All results are expressed as mean values with standard errors. All results were
compared using two-tailed paired t tests. Differences were considered significant at a
value of p< 05.
7.3 Results
7.3.1 General effects
Local infusion of bradykinin and angiotensin^ 1-7) caused no adverse or
systemic effects, and patients did not report any discomfort. Pulse rate (Figure 7.1),
blood pressure (Figure 7.2), and forearm blood flow in the non-infused forearm did
not change significantly during the initial infusions of bradykinin and angiotensin^ 1-
7). Nor was there any significant haemodynamic change during the co-infusion of
bradykinin and angiotensin^ 1-7), by the end of which, 0.78pmol had been
administered in total, a dose which might reasonably have been expected to be
systemically active.
7.3.2 Effect of bradykinin
Bradykinin caused marked vasodilation which was rapid in onset (~1 minute)
and almost as rapid in offset (~5 minutes). There was obvious flushing of the whole
forearm at the highest dose of bradykinin in the majority of cases, although no patient
complained of this spontaneously. There was a clear dose-response relationship, with
peak vasodilation at the highest dose of 30 pmol/min and no sign of the development
of significant tachyphylaxis (Figure 7.3).
7.3.3 Effect of angiotensin-^1-7)
There was evidence of slight vasoconstriction to angiotensin^1-7) at 500
pmol/min (4.3±3.0%) and 5000 pmol/min (6.7+3.8%) but not at lower or higher
doses. Even this effect was so small, however, that it was not significantly different
from baseline (Figure 7.4)
7.3.4 Effect of angiotensin-(l-7) on bradykinin
Co-infusion of bradykinin and angiotensin-(l-7) after 30 minutes of
angiotensin^ 1 -7) infusion gave very similar results to the initial infusion of bradykinin
alone. If anything, there was a slight reduction in response, although this difference
was not significant (Figure 7.1). This small but non-significant reduction could also
have been due to slight tachyphylaxis.
7.4 Discussion
In this study in the forearm of patients with heart failure treated with an ACE
inhibitor, we have shown that exogenous bradykinin causes vasodilation, that
angiotensin^ 1-7) has no significant effect on its own (except, if anything, a tendency
to slight vasoconstriction) and that it does not potentiate the response to exogenous
bradykinin (if anything, it inhibits it). These findings do not accord with previously
reported findings in animals (many of them in vitro rather than in vivo) and therefore
deserve further consideration.
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7.4.1 Effect of bradykinin in heart failure
Our findings with bradykinin in this study replicate and validate our findings
with bradykinin in chapters 5 and 6. The findings from this study confirm that
bradykinin is a potent vasodilator in patients with heart failure, as it is in subjects
without heart failure. As we have already observed it has recently been reported that
responses to bradykinin are unimpaired in an animal model of heart failure (Su et al,
1998), but at the time ofwriting ours are the only studies of the effect of bradykinin in
humans with heart failure in the entire literature (Davie et al, 1999).
7.4.2 Effect of angiotensin-(l-7) in heart failure
It was surprising that angiotensin-^ 1 -7) had so little haemodynamic effect on
its own and even more surprising that what effect it did have tended towards
vasopressor effects rather than vasodepressor ones. At first sight this appears to
contradict the substantial body of evidence reviewed in our introduction. Again,
however, we point to the potential importance of the species gap. We find that our
findings are consistent with the only three in vivo human studies in the literature.
Firstly it was shown that a systemic infusion of angiotensin-^ 1-7) has pressor effects,
albeit at a dose 24 times higher than the total dose we gave, and 3600 times higher
than an equipotent dose of angiotensin II (Kono et al, 1986). Secondly, we are aware
of two human studies that are cited as evidence that ACE inhibitors increase
angiotensin-) 1-7) levels. Lawrence et al (1990) appeared to show convincing
elevations in angiotensin-) 1-7) levels (and many other angiotensins) in hypertensive
patients treated with ACE inhibitors. Enthusiasm for these results must be tempered
by the fact that the comparison was with a case-control group of normotensive males,
rather than a comparison between the effects of treatment and non-treatment. Luque
et al (1996) examined the effects of treatment, and appeared to show that angiotensin-
(1-7) levels were increased by a last dose of captopril at the end of 6 months of
treatment with captopril. Even that increased level, however, was not as high as the
pre-treatment level, which was itself unaffected by the first dose of captopril. This
was in marked contrast to the effects of captopril on angiotensin I levels. We contend
that the available evidence suggests that angiotensin^1-7) is biologically inactive in
the circulation of man (certainly in the forearm of patients with heart failure treated
with an ACE inhibitor). Our findings leave open the possibility (as alluded to in our
introduction) that angiotensin^ 1-7) is acting as an ACE inhibitor (given that our
patients were already all on treatment with an ACE inhibitor). To test the hypothesis
that angiotensin^ 1-7) acts as an ACE inhibitor in humans it will obviously be
necessary to test the effect of angiotensin^ 1-7) in patients not treated with an ACE
inhibitor.
7.4.3 Angiotensin^ 1-7) and bradykinin in heart failure
We could find no evidence of any influence of quite massive doses of
angiotensin^ 1-7) on the response to bradykinin. It was important to demonstrate this
in man, given the very clear demonstration that angiotensin^ 1-7) potentiates the
effects of bradykinin in animal models (Paula et al, 1995). Indeed, it has been
reported that the effects of angiotensin-(l-7) itself are mediated by bradykinin. It has
also been reported that angiotensin^ 1-7) acts as an ACE inhibitor. It is obviously
possible that an ACE inhibiting and/or bradykinin-potentiating effect was obscured by
the fact that all our patients were already on an ACE inhibitor (if angiotensin^ 1 -7) is
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an ACE inhibitor, it is certainly not as powerful a one as enalapril and related drugs)
(Chappell et al, 1998). A lack of effect on the response to bradykinin is however
compatible with the lack of effect of angiotensin-(l-7) alone which we have also
demonstrated. Again, it does leave open the possibility that angiotensin-^ 1-7) might
potentiate bradykinin by acting as an ACE inhibitor (if studied in patients not treated
with an ACE inhibitor).
7.4.4 Summary
We have demonstrated that angiotensin-^ 1-7) has no significant effect on its
own, or on the response to bradykinin, in the forearm arteries of patients with heart
failure treated with an ACE inhibitor (who otherwise have quite impressive responses
to bradykinin). These are patients in whom the renin-angiotensin-system is of
considerable pathophysiological and therapeutic importance. Angiotensin^ 1-7) has
gained some currency as a potential mediator of "non-angiotensinergic" (or more
properly, "non-angiotensin-ll-ergic") effects of ACE inhibitors, and perhaps, other
modulators of the renin-angiotensin-system, such as ATI antagonists. Our results
militate against any such role, and suggest both that it will be necessary to look
elsewhere for mediators to explain the complexity of this system, and indeed that it
may be a fruitless task to look for a pathophysiological role of angiotensin-( l-7) in
humans with heart failure.
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Table 7.1 Patient Characteristics
Patient Characteristic
Sex, n 5 M/3 F
Age, y (mean +/- SD) 74 +/- 4
Weight, kg (mean +/- SD) 72 +/- 9
Primary diagnosis IHD/IDC, n 7/1
NYHA class II/III/IV, n 3/3/2
LVEF, % (mean +/- SD) 17+/-9
Current smoker, n 1
On Aspirin, n 6




Calcium antagonist, n oJ
Statin, n 1
Amiodarone 2
Baseline BP, mmHg (mean) 124/67
IHD = ischaemic heart disease; IDC = idiopathic dilated cardiomyopathy; NYHA =
New York Heart Association; LVEF = left ventricular ejection fraction
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Figure 7.1 Heart rate before, during and after angiotensin^ 1-7) infusion
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Figure 7.2 Mean blood pressure before, during and after angiotensin-) 1-7)
infusion
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Figure 7.3 Effect of bradykinin on forearm blood flow prior to and during
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Plasma fibrinolytic variables in heart failure
8.1 Introduction
It is not just vasoactive substances which are released by the endothelium. In
particular, a number of components of the fibrinolytic system are also produced by
endothelial cells, specifically, tissue-type plasminogen activator (TPA) and
plasminogen activator inhibitor type I (PAI-1). TPA converts plasminogen to plasmin
which is the active principle of fibrinolysis, and PAI-1 inhibits TPA itself (Figure 8.1).
Endothelial cells also release von Willebrand Factor (VWF) which interacts more
indirectly with the fibrinolytic system and the clotting cascade by acting as a carrier
for factor VIII and by participating in the process of platelet adhesion to damaged
endothelium. Recognition of the fact that elevated levels of VWF were associated
with endothelial cell damage predated the concept of endothelial dysfunction by some
years (Boneu et al, 1975). Indeed, TPA, PAI-1 and VWF have all been proposed as
markers of endothelial dysfunction. In the case of TPA and PAI-1, however, the
situation is complicated by their responsiveness to hormonal stimulation of the
endothelium. In the case of TPA, release appears to be stimulated by bradykinin
(Brown et al, 1997), and in the case of PAI-1, release appears to be stimulated by
angiotensin II (Ridker et al, 1993). It is hardly surprising that a number of studies
have attempted to examine the effect of ACE inhibitors and other modulators of the
renin-angiotensin-system on TPA, PAI-1, VWF and D-dimers, the end product of the
fibrinolytic system (Figure 8.1).
As shown in Table 8.1, these studies have been extremely heterogeneous in
aims, design and methods, but despite this there are only four studies which have been
completely "negative", and the other nine have been more or less "positive". None
showed any increase in any of these fibrinolytic parameters, so probably can be taken
as evidence that ACE inhibitors tend to decrease some or all. This is assuming no
publication bias, which seems unlikely, in the presence of so many "negative" results.
This body of evidence has been cited as a possible explanation of the unexpected
reduction in coronary events demonstrated with captopril in the SAVE study (Pfeffer
et al, 1992). Only two of these studies have taken advantage of the opportunity to
compare an ACE inhibitor with an AT I antagonist (Goodfield et al, 1999; Brown et
al, 1999). The first of these studies (in patients with heart failure) showed that
losartan reduced PAI-1 antigen more than enalapril, and cited this as a possible
explanation of the unexpected reduction in mortality with losartan demonstrated in the
ELITE study (Pitt et al, 1997), but this was a study of the effects of a single dose
only. The second study (in normals only) showed that quinapril but not losartan
reduced PAI-1 activity and antigen, and that losartan but not quinapril reduced TPA
antigen. We wanted to compare the effects of ACE inhibition and ATI antagonism
on plasma fibrinolytic variables in patients with heart failure over a rather longer
period of time than the single dose previously studied. We therefore randomised
patients with heart failure to double-blind cross-over treatment with enalapril and
losartan (five weeks each) and measured the effect on fibrinolytic parameters.
8.2 Methods
8.2.1 Patients
The study was conducted with the approval of the West Ethics Committee and
all patients gave written informed consent. Twelve patients with chronic heart failure
secondary to left ventricular systolic dysfunction confirmed by echocardiography were
studied (left ventricular ejection fraction <40%). All patients were treated with an
ACE inhibitor at baseline (enalapril lOmg bd in the majority). All medication apart
from ACE inhibitor/ATI antagonist aspirin was constant throughout the study.
Patient characteristics are shown in Table 6.1
8.2.2 Randomisation
Patients were randomised to double-blind cross-over treatment with enalapril
lOmg bd for 5 weeks followed immediately by losartan 25mg bd for 5 weeks, or vice
versa. At the end of each 5 weeks patients attended for study, having abstained from
all aspirin therapy for 14 days. Patients took all their other usual medication including
study treatment at 8am before attendance on the day of study at 2pm. It has long
been known that plasma fibrinolytic parameters exhibit significant diurnal variation
(Angleton et al, 1989). Although we were not in a position to examine this
variability, it was clearly important that all our studies were performed at the same
time.
8.2.3 Measurements
Supine blood pressure and pulse rate were manually recorded using a mercury
sphygmomanometer. After lying supine for 20 minutes, 10ml of blood was withdrawn
from the antecubital fossa of the right forearm, collected into sodium citrate tubes and
kept on ice before being centrifuged at 3000rpm for 20 minutes at 4°C. Platelet-free
plasma was then decanted and stored at -80°C before assay. PAI-1 activity was
measured with a commercially available chromogenic substrate assay (Coatest PAI;
Chromogenix, Epsom) and compared with a pool of normal results to give the result
as a percentage of that normal pool. TPA was measured with a commercially
available enzyme-linked immunosorbent assay (ELISA) from Biopool AB, Umea,
Sweden. Von Willebrand factor (VWF) antigen was measured with an in-house
ELISA using rabbit anti-human polyclonal antibodies from DAK.0 pic, High
Wycombe. Fibrin D-dimer was measured with a commercially available ELISA from
Biopool AB, Umea, Sweden. These are all routine assays, well-established in our
department (Sattar el al, 1999).
8.2.4 Data analysis
All results are expressed as mean values with standard errors. All results were
compared using two-tailed paired t tests. Differences were considered significant at a
value of p< 05.
8.3 Results
8.3.1 General effects
Haemodynamic and fibrinolytic parameters are shown in Table 8.2. There was
no significant difference in pulse rate and blood pressure between either of the studies
(although there was a trend towards a lower blood pressure in the enalapril study
compared with the losartan study).
8.3.2 Fibrinolytic parameters
Fibrinolytic parameters are shown in Table 8.2 and Figure 8.2. There was no
significant difference in any of the fibrinolytic parameters studied between either of
the studies, and all were within the normal range for our laboratory. Despite the
changes previously demonstrated, we found no difference in TPA or PAI-1. Despite
its association with endothelial function, we found no difference in VWF. Despite its
status as an endpoint of the fibrinolytic system, we found no difference in D-dimer.
8.4 Discussion
We have shown that there is no significant difference in plasma fibrinolytic
variables after 5 weeks of enalapril lOmg bd and after 5 weeks of losartan 25mg bd, in
patients with heart failure. In particular, we have failed to show any difference
whatsoever in PAI-1 activity. This is despite the fact that it has previously been
shown that a single dose of losartan 50mg reduces PAI-1 antigen more than a single
dose of enalapril lOmg in patients with heart failure (Goodfield et al, 1999). It is also
despite the fact that it has recently been shown that it is angiotensin-(3-8) (angiotensin
IV) acting at the angiotensin type 4 (AT4) receptor which mediates PAI-1 release by
endothelial cells (Kerins et al, 1995; Gesualdo et al, 1999). More recently it has been
shown that 10 days of quinapril 40mg bd reduced PAI-1, but 10 days of losartan
50mg bd reduced TPA antigen (Brown et al, 1999). These findings appear to be
somewhat contradictory, and the apparent discrepancy deserves closer consideration.
8.4.1 Acute versus chronic effects
If acute ATI antagonism reduces PAI-1 more than acute ACE inhibition, it
would be expected that chronic ATI antagonism would also reduce PAI-1 more than
chronic ACE inhibition. In fact there was no difference. It is impossible to say
whether this was because the ACE inhibitor and the ATI antagonist were equally
effective or because they were equally ineffective. Assuming that their acute effects
were as previously demonstrated, it is impossible to say whether with chronic ACE
inhibition PAI-1 falls further or with chronic ATI antagonism PA1-1 drifts up again.
It certainly suggests that there is a potential distinction to be made between the acute
and chronic effects ofATI antagonism and ACE inhibition. It is already well known
that chronic effects ofACE inhibitors may differ from their acute effects (Sharpe et al,
1980). It is not known to what extent the chronic effects of ATI antagonists might
differ from their acute effects. This only emphasises how important it is that acute
studies are complemented by more chronic studies. Under these circumstances, to
find that there is a discrepancy between the acute and chronic effects of ATI
antagonism and ACE inhibition on PAI-1 in patients with heart failure is hardly
surprising.
8.4.2 Diurnal variation
It is equally possible that the difference between our findings and previous
studies is accounted for by some difference in timing relative to the diurnal variation
of plasma fibrinolytic variables. We took care, however, to make sure that our timing
was consistent from study to study, and not more than an hour or two different from
previous studies. Diurnal variation of plasma fibrinolytic variables is not so rapid as
make much difference because of a few hours either way during the day.
8.4.3 Drug effects
It is obviously possible that the discrepancy between this study and the
previous one is accounted for by some factor other than timing (although timing is the
most obvious difference). It is interesting to note that, whereas we discontinued all
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aspirin therapy 14 days before study, there is no mention of this in the previous study
(8 out of 12 of our patients were treated with aspirin, compared to 13 out of 20 in the
previous study). This actually raises the tantalising possibility that the difference
between our results and previous results may be due to an interaction with the effects
of aspirin. We used exactly the same drugs (enalapril and losartan) and exactly the
same sort of patients (patients with stable chronic heart failure), but there is a
difference in dosing. Whereas we used enalapril 20mg a day and losartan 50mg a day,
the previous study used a single dose of enalapril lOmg and losartan 50mg. The
doses we used were based on the evidence of the best available clinical trials. The
dose of enalapril came from the Studies of Left Ventricular Dysfunction (The SOLVD
Investigators, 1991; 1992). The dose of losartan came from ELITE (Pitt et al, 1997).
This raises the very real possibility that the difference between losartan and enalapril
shown in the previous trial is dose-dependent, the difference being between the
response to a whole day's dose of losartan and half a day's dose of enalapril. Of
course, it is difficult to compare a long-acting drug with a shorter-acting drug, either
acutely or chronically. Even so, it is hardly surprising that a study effectively
comparing the same dose of losartan with double the dose of enalapril has redressed
the balance. In this context, it is very interesting that a study comparing the effects of
a very large dose of quinapril for 10 days with double the dose of losartan for 10 days
did find a difference between them. Despite this, the authors were unable to attach
any qualitative clinical significance to the fact that quinapril reduced PAI-1 more and
losartan reduced TPA more (Brown et al, 1999). Whatever the case, it is clearly
important that the message that ATI antagonism has more beneficial effects on
plasma fibrinolytic variables than ACE inhibition does not go uncontradicted.
Figure8.1
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Table 8.2 Effect of losartan and enalapril on systemic haemodynamics and
fibrinolytic parameters
Enalapril Losartan
Heart rate, bpm 67±5 63+3
Mean arterial pressure, mmHg 92±4 99+4
TPA antigen, ng/ml 13+1 15±1
PAI-1 activity, % 99±7 101±8
VWF, HJ/dl 122+15 117+13
D-dimer, ng/ml 80+26 64+11
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Plasma nitrate/nitrite concentrations in heart failure
9.1 Introduction
A consistent feature of vascular biology over the last few years has been the
finding that stimulated nitric oxide release (the syndrome of endothelial dysfunction) is
reduced in heart failure (Kaiser et al, 1989; Treasure et al, 1990; Kubo et al, 1991;
Drexler et al, 1992). Despite this, attempts to define the level of basal nitric oxide
release in heart failure have been somewhat inconsistent, partly because they have
relied on indirect methods. The earliest efforts used L-NG-monomethylarginine (L-
NMMA), an inhibitor of nitric oxide synthesis. These gave results that implied that
basal nitric oxide release was increased (Drexler et al, 1992, Habib et al, 1994),
unchanged (Kubo et al, 1994) or reduced (Katz et al, 1996). Plasma nitrate levels
also gave results which implied that basal nitric oxide release was increased (Winlaw
et al, 1994). Previously, exhaled nitric oxide levels had implied that basal nitric oxide
release was reduced (Adachi et al, 1997), but very recently it has been conclusively
demonstrated that exhaled nitric oxide is not vascular endothelial in origin, but
alveolar epithelial (Sartori et al, 1999). Over the same period of time, molecular
biology has been attempting to disentangle the intricacies of nitric oxide synthase
(NOS) gene expression in heart failure, the results of which have been reasonably
consistent. The majority of studies have found reduced expression of the
constitutional form of NOS (endothelial cell NOS, ecNOS or NOS 111), both in
endothelial cells (Smith et al, 1996; Wang et al, 1997; Gaballa et al, 1999) and in
myocardial cells (Drexler et al, 1998). Similarly the majority of studies have found
increased expression of inducible NOS (iNOS or NOS II), both in myocardial cells
(Haywood et al, 1996; Satoh et al, 1997; Drexler et al, 1998) and in skeletal muscle
(Riede et al, 1998). What this actually means for overall NOS activity and overall
nitric oxide release is obviously very difficult to say. Very recently, the issue appears
to have been settled once and for all. Katz et al (1999) used a radioisotope labelled
tracer to track actual whole body nitric oxide synthesis. This showed that basal and
stimulated (by exercise) nitric oxide synthesis were both reduced in patients with heart
failure.
At the same time as the above, the idea has emerged that angiotensin
converting enzyme (ACE) inhibitors might actually help restore impaired endothelial
function (i.e., stimulated and possibly basal nitric oxide release) in heart failure
(Mancini et al, 1996). This could be an important difference between ACE inhibitors
and angiotensin II type I receptor (ATI) antagonists, especially as it has been
suggested that the improvement in endothelial function from an ACE inhibitor might
be bradykinin-dependent. It has also been suggested that the improvement in
endothelial function from an ACE inhibitor might actually be blocked by aspirin.
Nakamura et al (1994) found that co-infusion of enalaprilat enhanced vasodilation to
acetylcholine before, but not after, pre-treatment with aspirin. It was particularly for
this reason that we were interested in some sort of comparison of endothelial function
between patients with heart failure treated with an ACE inhibitor and an ATI
antagonist, whilst off aspirin. Any difference between the two might represent a
potential substrate for an interaction with aspirin by one, but not the other. For the
purposes of this study patients with heart failure were therefore randomised to
double-blind cross-over treatment with an ACE inhibitor and an ATI antagonist (five




The study was conducted with the approval of the West Ethics Committee and
all patients gave written informed consent. Twelve patients with chronic heart failure
secondary to left ventricular systolic dysfunction confirmed by echocardiography were
studied (left ventricular ejection fraction <40%). All patients were treated with an
ACE inhibitor at baseline (enalapril lOmg bd in the majority). All medication apart
from ACE inhibitor/AT I antagonist and aspirin was constant throughout the study.
Patient characteristics are shown in Table 6.1
9.2.2 Randomisation
Patients were randomised to double-blind cross-over treatment with enalapril
1 Omg bd for 5 weeks followed immediately by losartan 25mg bd for 5 weeks, or vice
versa. At the end of each 5 weeks patients attended for study, having abstained from
all aspirin therapy for 14 days. Patients took all their other usual medication including
study treatment (including nitrate treatment if applicable) at 8am before attendance on
the day of study at 2pm having fasted for 6 hours (but otherwise having taken their
normal diet).
9.2.3 Measurements
Supine blood pressure and pulse rate were manually recorded using a mercury
sphygmomanometer. After lying supine for 20 minutes, 10ml of blood was withdrawn
from the antecubital fossa of the right forearm, collected into heparinised tubes and
kept on ice before being centrifuged at 3000rpm for 20 minutes at 4°C. Platelet-free
plasma was then decanted and stored at -80°C before assay. Total nitrite plus nitrate
concentration was assayed as described by Phizackerley & Al-Dabbagh (1983). To
reduce nitrate to nitrite, supernatant or standards were incubated at room temperature
in the presence of Klebsiella pneumoniae under anaerobic conditions. Total nitrite in
the supernatant was subjected to the Griess reaction (Green et al, 1982) and assayed
spectrophotometrically. Data are reported as the sum of nitrite plus nitrate. Normal
values in our laboratory were 5-15 mmol/L. The limit of detection was 0.1 mmol/L.
9.2.4 Data analysis
All results are expressed as mean values with standard errors. All results were




Haemodynarnic parameters are shown in Table 8.2. There was no significant
difference in pulse rate and blood pressure between either of the studies (although
there was a trend towards a lower blood pressure in the enalapril study compared with
the losartan study).
9.3.2 Effect on plasma nitrate/nitrite concentrations
Plasma nitrate/nitrite levels are shown in Figure 9.1. There was no significant
difference in nitrate/nitrite levels between either of the studies (although there was a
trend towards higher levels in the enalapril study compared with the losartan study).
There was no evidence whatsoever of any association between plasma nitrates/nitrite
levels and blood pressure. There was also no significant difference in nitrate/nitrite
levels between the 3 patients who were on habitual treatment with nitrates and the 9
patients who were not.
9.4 Discussion
We have shown that there is no significant difference in nitrate/nitrite levels
after 5 weeks of enalapril lOmg bd and after 5 weeks of losartan 25mg bd, in patients
with heart failure. To our knowledge this is the first time that any such comparison
has been reported, especially in humans with heart failure. The data from animal
models of endothelial dysfunction is somewhat contradictory.
9.4.1 Animal versus human studies
Some studies indicate that ACE inhibitors and ATI antagonists improve
endothelial function equally (Rodrigo et al, 1997; Hoshino et al, 1998; Teisman et al,
1998). Other studies indicate that ACE inhibitors improve endothelial function more
than ATI antagonists (Berkenboom et al, 1997). In some cases this appears to be
because of a bradykinin dependent mechanism (Berkenboom et al, 1997). In humans
there is a study which shows that quinapril and losartan both improved postprandial
endothelial dysfunction (Wilmink et al, 1999), although quinapril did so more than
losartan. There is also an ongoing study which has been reported to show that
quinapril improves endothelial dysfunction in patients with coronary disease, but that
enalapril and losartan do not (Anderson, 1999).
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9.4.2 Blood pressure and aspirin therapy
The small but not significant difference in nitrate/nitrite levels we recorded
between enalapril and losartan might be taken as confirmation of a prejudice that ACE
inhibitors are in some way superior to ATI antagonists, especially as it went the same
way as a small difference in blood pressure. This was despite the fact that there was
no evidence of any association between nitrate/nitrite levels and blood pressure. It
would obviously be interesting to see if there was any association between
nitrate/nitrite levels and aspirin therapy, especially as it has been suggested that ACE
inhibitors might improve endothelial function by bradykinin-mediated, prostaglandin-
dependent mechanism. It was for this reason that we withheld aspirin therapy, to
make sure that it was not a confounding influence.
9.4.3 Superoxide pathway of endothelial dysfunction
Recently evidence has come about that one pathway of development of
endothelial dysfunction might relate to angiotensin II activation of endothelial
NADPH-oxidase to produce superoxide which neutralises nitric oxide (Rajagopalan el
at, 1996). This is obviously a mechanism by which ACE inhibitors and ATI
antagonists might influence endothelial function directly, with an obvious effect on
plasma nitrate/nitrite concentrations. The absence of any significant difference
between ACE inhibitors and ATI antagonists with respect to nitrate/nitrite
concentrations does not tell us whether this pathway is important or not, but does




The absence of any significant difference in nitrate/nitrite levels between
patients with heart failure treated with enalapril and the same patients treated with
losartan can hardly be taken to prove that there is no difference in the effects of these
agents on endothelial function. Although it is reasonable to postulate that there might
be a correlation between nitrate/nitrite levels and more conventional measures of
endothelial function in the form of endothelium-dependent vasodilatation, we are not
aware of any evidence that there is such a correlation. It would have been better to
look at endothelium-dependent vasodilatation in our patients as well, but we did not
have the opportunity to do so, and we did have the opportunity to look at
nitrate/nitrite levels. We found no evidence that there is any difference between
enalapril and losartan in this regard, at least as far as patients with heart failure are
concerned. The finding should perhaps be regarded as hypothesis-generating only,
and subjected to further experimental scrutiny with more conventional measures of
endothelial function, especially given the lack of human data and the inconsistency of
the animal data alluded to above.
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Figure 9.1 Plasma nitrate/nitrite levels in patients with heart failure treated




10.1 Chapter 3 Effect of arachidonic acid in heart failure
The studies described in chapter 3 demonstrate that arachidonic acid is
vasodilating in forearm resistance arteries in healthy volunteers and in patients with
heart failure treated with an ACE inhibitor. This is a very similar result to the effect
of arachidonic acid in the hand veins of healthy volunteers (Bhagat et al, 1995).
There was no particular reason to suppose that this would be the case, however, given
the pluripotentiality of arachidonic acid alluded to in chapter 1, and the variability of
results from animal studies alluded to in chapter 3. These two pieces of evidence
imply that vasodilator metabolites of arachidonic acid predominate in the circulation
of man, potentially across a wide spectrum of health and disease, and across a wide
spectrum of vasoactive therapy. We have no information on whether the response
demonstrated is endothelium-dependent or endothelium-independent, but it does not
appear to be significantly impaired by heart failure (in patients with presumed
endothelial dysfunction, even though we did not demonstrate this independently). It
would obviously have been interesting to correlate the effect we observed with more
conventional vasodilator responses, such as the response to acetylcholine versus
nitroglycerin. Our overriding interest, in examining the effects of arachidonic acid,
however, was to find a vascular response which might act as a substrate for the
vascular effects of aspirin. As we have repeatedly observed, aspirin does not appear
to have any immediate direct vasoactive effect on its own, so elucidation of its
vascular effects does appear to necessitate examination of more complicated
interactions. Examination of the effect of aspirin on the response to arachidonic acid
is the perfect target for this, as any vasoactive effects that aspirin does have must
occur via its effect on cyclooxygenase, and therefore on metabolism of arachidonic
acid (Vane et a/, 1971). The fact that we demonstrated that aspirin did impair
vasodilation to arachidonic acid in patients with heart failure treated with an ACE
inhibitor does not prove that aspirin affects vascular tone in these patients, but it does
prove that it could, even at a very low dose. In our subsequent studies, we have
attempted to home in on some of the pathways that might be involved if aspirin does
affect vascular function in heart failure. In some of our studies, we have directly
assessed the effect of aspirin therapy itself, but in some of them we have only directly
assessed the effect of conventional heart failure treatment.
10.2 Chapter 4 Interaction of aspirin and furosemide in heart failure
The studies described in chapter 4 demonstrate that furosemide (a mainstay of
the treatment of heart failure) has acute venodilator effects which may be blocked by
clinically relevant doses of aspirin (indeed, in this case, they were reversed). In case it
could be claimed that the effect observed was not clinically relevant, we compared our
results with the effect of sublingual glyceryl trinitrate (the archetypal vasodilator in
clinical practice). We found that the vasodilator response demonstrated with
furosemide was very similar to that with GTN (with a similar effect on venous
capacitance and a similar lack of effect on forearm blood flow, pulse and blood
pressure). Furthermore, these results are strikingly similar to our results in chapter 3
(with significant inhibition by both 75mg and 300mg aspirin, and no significant
difference between the two, although there was more inhibition by 300mg than 75mg)
and serve to provide compelling validation of both sets of results.
158
10.3 Chapter 5 Effect of bradykinin and substance P in heart failure
The studies described in chapter 5 demonstrate that bradykinin and substance
P are both potent vasodilators in patients with heart failure treated with an ACE
inhibitor. More importantly, from our point of view, we showed that neither of them
is significantly affected by aspirin, whether intra-arterial or oral (at a dose shown in
chapter 3 to be capable of affecting vascular responses). Both sets of findings are a
little controversial. There is some controversy over whether the defect in endothelial
dysfunction is specific or generalised. In part, this relates to the difficulty of
dissociating stimulated vascular responses from the effect of basal vascular tone. If
basal blood flow is reduced (as it usually is in heart failure and other causes of
endothelial dysfunction, even on treatment), it is obvious that absolute increases in
blood flow cannot be taken as representative, but there is no guarantee that relative
increases in blood flow are any more representative. In any case, our findings suggest
that the responses to bradykinin and substance P are not significantly impaired in
patients with heart failure. This suggestion is tentative because we did not have a
control group for comparison, and it is comparison with previous work which makes
the suggestion. We can be more definite about the fact that aspirin did not affect the
response to bradykinin or substance P. Although it is a commonplace of vascular
biology that bradykinin is responsible for prostaglandin-dependent, non-
angiotensinergic effects of ACE inhibitors, the evidence that the vasodilator effects of
bradykinin are prostaglandin-dependent is already inconsistent, as we have pointed
out in chapters 3 and 5. Our findings in chapter 5 make it even less likely that the
effects of bradykinin (or substance P) are affected by aspirin, even if bradykinin does
contribute to the beneficial effects of ACE inhibitors. In other words, bradykinin and
substance P are unlikely to contribute to the interaction between the effects of aspirin
and the effects of ACE inhibitors (if indeed such an interaction exists).
10.4 Chapter 6 Effects of bradykinin antagonism in heart failure
In chapter 5 we showed that bradykinin is unlikely to be affected by aspirin.
In chapter 6 we looked at the other side of the proposed interaction between aspirin
and ACE inhibitors. It is well-established that ACE inhibitors potentiate the effects of
exogenous bradykinin. Despite this, there is little evidence that potentiation of
endogenous bradykinin actually contributes significantly to the beneficial effects of
ACE inhibitors. The studies described in chapter 6 demonstrated that an antagonist of
endogenous bradykinin had no discernible effect on vascular tone in patients with
heart failure. This was irrespective of treatment with an ACE inhibitor (which might
have been expected to potentiate endogenous bradykinin) or an ATI antagonist
(which might not, at least not directly). We should be careful not to over-interpret
these findings, especially in the light of a recent publication which showed that an
antagonist of endogenous bradykinin attenuated the haemodynamic effects of an ACE
inhibitor given to patients with hypertension (Gainer el al, 1998). We should be
careful not to over-interpret those findings either, as there are many differences
between the two studies which certainly raise as many questions as they answer. In
any case, our findings in chapter 6 (together with our findings in chapter 5) imply that
the suggestion that bradykinin is an intermediary between the effects of ACE
inhibitors and aspirin should be treated with extreme caution.
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10.5 Chapter 7 Effect of angiotensin-(l-7) in heart failure
Having disposed of bradykinin and substance P as potential mediators of an
interaction between aspirin and ACE inhibitors, we turned our attention to the greater
complexity of the renin-angiotensin-system itself As we observed in chapter 1, there
are a large number of angiotensins, which had previously been regarded as mere
degradation products. More recently, it has been realised that many of these are
detectable in the circulation, that many of them are actually potentiated by treatment
with ACE inhibitors, and that some of them are certainly vasoactive. Despite this,
there is almost no work on humans, and none in heart failure. Most of the recent
interest has focussed on the effects of angiotensin^ 1-7). In particular, animal work
has included complex interactions of angiotensin^ 1-7), ACE inhibitors, bradykinin
and prostaglandin synthase inhibitors (indomethacin, rather than aspirin). Despite
this, we found that we could not sustain a significant vasoactive effect of angiotensin-
(1-7) in the vasculature of patients with heart failure treated with an ACE inhibitor.
Although it is possible that we would have obtained a different result in patients not
treated with an ACE inhibitor, we were able to point out that our findings were
consistent with the very small body of work in humans, both normal and hypertensive,
treated with an ACE inhibitor and not. It certainly seems unlikely that angiotensin-(l-
7) contributes to any interaction between aspirin and ACE inhibitors.
10.6 Chapter 8 Plasma fibrinolytic variables in heart failure
As we pointed out in chapter 8, there is extensive evidence that conventional
heart failure treatment in the form of ACE inhibitors affects plasma fibrinolytic
parameters. There is also some evidence that more modern heart failure treatment in
the form of AT 1 antagonists affects plasma fibrinolytic parameters differently. If this
is the case, it must presumably reflect a non-angiotensinergic effect, or at least a non-
angiotensin-II-ergic effect. If that is the case, it might be a prostaglandin-dependent
effect, which might interact with the effects of aspirin. We took great care to study
our patients off aspirin therapy (care which previous studies appear not to have
taken), and found no evidence of any difference between ACE inhibitors and ATI
antagonists in this regard. There seemed little gain, therefore, from examining the
additional effect of aspirin therapy, if any, on our treatment. It might still be
interesting to do so. It is obvious that aspirin, through its antiplatelet effects, has
complex interactions with the circulating fibrinolytic system, and indeed aspirin has
been shown to enhance plasma fibrinolytic variables (Moroz, 1977). Despite this, we
are not aware of any reports of the effect of aspirin on fibrinolysis being mediated via
effects on endothelium.
10.7 Chapter 9 Plasma nitrate/nitrite concentrations in heart failure
Although we did not have the opportunity to examine the interaction of any of
our treatment with conventional measures of endothelial function (for example, the
response to acetylcholine versus nitroglycerin), we were able to examine the effect on
nitrate/nitrite levels. This is obviously an indirect measure of endothelial function, but
has been at least partially validated in this regard. We found that there was no
significant difference between ACE inhibitor and ATI antagonist treatment. To date,
there has been very little comparison of endothelial function between ACE inhibitors
and ATI antagonists, especially in heart failure, so this is a useful piece of
information, despite its limitations. In particular, we have no information on whether
this was because the two treatments were equally effective, or equally ineffective. If
there really is no difference in endothelial function between patients treated with ACE
inhibitors and patients treated with ATI antagonists, it makes it less likely that the
improvement in endothelial function with ACE inhibitors (if any) is due to
potentiation of bradykinin, unless ATI antagonists are potentiating bradykinin in some
way as well Of course, our findings in chapter 5 cast doubt upon the potentiation of
bradykinin itself, by either ACE inhibitors or ATI antagonists. We were not able to
examine the effect of aspirin on this aspect of endothelial dysfunction. It would have
been interesting to do so, given the conflicting reports in this regard. Once again,
however, the lack of any difference between ACE inhibitors and AT I antagonists
whilst off aspirin therapy weakened our resolve to look for a difference between them
whilst on aspirin therapy.
10.8 Further studies
We have not completely characterised the effects of arachidonic acid, nor have
we completely characterised the effects of heart failure on the response to arachidonic
acid. Apart from correlating the effects of arachidonic acid with more conventional
measures of endothelial dysfunction, it would be interesting to test arachidonic acid in
a wider patient group, including an appropriate control group (difficult as it can be to
define an appropriate control group for heart failure patients). It would also be
interesting to test the effect of lower doses or different formulations of aspirin (such
as modified-release or dermal aspirin). Similarly, we have not characterised the
effects of bradykinin and substance P as completely as we might, with an appropriate
control group. Our findings with bradykinin-antagonism and enalapril and losartan
are amongst our most interesting findings, not least because they are at odds with our
expectations and previous findings. Our hypothesis that the difference between our
findings and previous findings is due to timing deserves to be tested, with
simultaneous examination of acute and chronic effects under more similar conditions
(this would also allow re-examination of plasma fibrinolytic parameters to resolve a
similar inconsistency). It is also possible that the lack of effect of bradykinin-
antagonism is down to a lack of effect at rest. We would like to examine the
interaction, if any, between bradykinin antagonism and flow-dependent dilatation and
any influence of enalapril and losartan. It would certainly be interesting to test the
effect of angiotensin^ 1-7) in a different patient group, as we found no effect in
patients with heart failure treated with an ACE inhibitor. We would also like to
examine the effect, if any, of A-779 which is a recently available antagonist of
angiotensin^ 1-7).
10,9 Summary
Our main interest is in the vascular effects of aspirin and ACE inhibitors (and
ATI antagonists) in patients with heart failure. Chapter 3 showed that arachidonic
acid and its metabolites may be important in the blood vessels of patients with heart
failure and that doses of aspirin in common use for cardioprotection have the potential
to interfere with this system. Chapter 4 showed that the same doses of aspirin had
similar effects on the venodilator response to furosemide in a completely different
vascular bed. Chapter 5 showed that despite this, there was no evidence that aspirin
had any effect on the potent vasodilators, bradykinin or substance P. Chapter 6
showed that there was little evidence that ACE inhibitors (or indeed ATI antagonists)
caused significant potentiation of endogenous bradykinin anyway. Chapter 7 showed
that angiotensin^ 1-7) was also unlikely to contribute to the etfects of ACE inhibitors
(or indeed AT 1 antagonists) as it seems to be inactive after all. Chapter 8 showed
that there was no significant difference between ACE inhibitors and AT 1 antagonists
in terms of their effects on plasma fibrinolytic variables. Chapter 9 showed that there
was no significant difference between ACE inhibitors and AT 1 antagonists in terms of
their effect on overall endothelial function in terms of plasma nitrate/nitrite levels
(which further militates against a role for bradykinin and/or prostaglandins). Taken
together these results suggest that whilst it is relatively easy to demonstrate that
aspirin could have detrimental effects in the vasculature of patients with heart failure,
it is very much more difficult to demonstrate that it is actually doing so. Similarly,
whilst it is relatively easy to conceive of differences between ACE inhibitors and AT 1
antagonists, it is very much more difficult to demonstrate that there actually are any.
Our findings confirm our view that whilst the vascular effects of aspirin are almost
certainly quite simple, the vascular effects of ACE inhibitors and ATI antagonists are
really quite complicated, yet much more difficult to dissociate from one another than
we had at first anticipated.
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